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ABSTRACT

According to the different phenotypes and distinct patterns of gene expression,
macrophages can be subdivided into two types: M1 and M2.

The M1 macrophages,

which are activated through the classical pathway, have a proinflammatory
characteristic, providing an in-front defense line against different kinds of pathogens
as well as malignant cells.

On the other hand, the M2 macrophages are

immunosuppressive and instead can promote tumor growth and dissemination.

The

solid tumor tissues are often infiltrated with a large number of macrophages, the
so-called tumor-associated macrophages (TAMs).

TAMs, which are polarized into

M2 phenotype under the tumor microenvironment, promote tumor progression by
favoring angiogenesis, extracellular matrix (ECM) remodeling, and tuning down of
adaptive immunity.

Although the molecular mechanisms underlying the process of

macrophage polarization is not fully understood, defective activation of NF-ĸB
signaling pathway has been frequently observed in TAMs.

Pharmacological skewing

of TAM polarization from an M2–like phenotype to a full M1 phenotype has been
shown to sustain antitumor immunity.

In the present study, a novel

macrophage-targeted, particulate-mediated gene delivery system was designed aiming
to modulate the activation status of the targeted macrophage cells for cancer therapy.
Using zymosan particles conjugated with recombinant adenoviruses encoding
different interferon regulatory factor (IRF) family genes, specifically IRF1, IRF3, and
IRF7, the current system, taking advantage of the characteristic of phagocytosis of
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macrophages as well as the capability of adenovirus to escape from the phagosomes,
achieved virtually 100% transduction efficiency in RAW-Blue macrophage cell line.
Through reporter assay, cytokine antibody array, and the measurement of NO
production, our results showed an increased NF-ĸB activity in the cells treated by the
adenovirus-zymosan conjugates.

In addition, cytokine antibody array analysis also

revealed increased expressions of many pro-inflammatory cytokines down-stream of
the NF-ĸB or IRF signaling pathway in treated cells.

This increased expression of

pro-inflammatory cytokines probably reflects an added effect from three different
sources: the effect elicited by the binding of zymosan to the TLR2; the effect from the
cells sensing viral dsDNA through TLR9-dependent and/or –independent pathways;
and the effects directly from the expression of the transfected IRF genes.

Further

works are needed to study the effects of the current system in primary mouse
macrophages, especially to test whether the transfected macrophages have elevated
activities against tumor cells.

Key Words: Tumor-associated Macrophages, Interferon Regulatory Factor, NF-ĸB,
Adenoviral Vector, Zymosan
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CHAPTER ONE
LITERATURE REVIEW

1. Tumor-associated macrophages (TAMs)
1.1. Introduction of TAMs
From a myriad of histological observations, the infiltration of a large number
of leukocytes has been considered as a characteristic of tumor tissues. Macrophages
in the tumor tissues, the so-called tumor-associated macrophages (TAMs), represent a
predominant population of mononuclear leukocytes in tumor stroma.

Thus, in the

study of tumor development and progression, an increasing interest has been focused
on the functions of tumor infiltrating leukocytes, especially the TAMs.
While a few tumors may grow as cell suspensions, for example leukemia and
ascites tumor, most tumors form into solid masses of tissues mainly composed of
malignant cells and stroma, which are two interdependent components of tumors and
function reciprocally.

The tumor stroma which is largely produced from normal host

tissue includes matrix components, blood vessels as well as inflammatory cells.
Malignant cells may alter the properties their stroma by cell-to-cell contact, soluble
factors and/or by modification of the extra-cellular matrix (ECM) in support of their
growth.

On the other hand, in response to malignant cells, the stromal cells are able

to modify the phenotypes, invasiveness and metastatic capacity of tumor cells,
typically promoting their progression. A vast diversity of molecules are produced by
different cellular components within the complex tumor microenvironment such as
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cytokines, chemokines, growth factors and proteases, which may positively or
negatively influence tumor survival and growth.
TAMs, as an important component of stroma, are originated from peripheral
blood monocytes in the blood circulation which are recruited into the tumor mass by
tumor-derived chemoattractants and then differentiated into tissue macrophages.
Originally, it was assumed that TAMs were a principal part of host defence against
developing tumors based on some early observations and the well-known important
roles of macrophages in the immune system (Knowles and Harris, 2007).

Although

the mechanisms by which TAMs interact with tumor cells are not fully understood,
recent works have suggested a very complicated role macrophages play in tumor
development and progression.

First of all, a number of observations showed that

TAMs may be involved in the inhibition of tumor growth.

By comparing the

cytotoxic activity of peritoneal macrophages (PMs) and peripheral blood monocytes
(PBMs) after in vitro activation with interferon-γ (IFN-γ) and lipopolysaccharide
(LPS), Wilbanks et al. suggested that PMs from ovarian cancer patients were
significantly more cytotoxic than those from non-activated controls (Wilbanks et al.,
1999).

In line with this result, another observation showed that the infiltration of

tumor-associated macrophages is inversely correlated with tumor progression in
human prostate cancer (Shimura et al., 2000). Additionally, the TAMs have been
identified to be able to orchestrate the production of various substances, such as IFNs,
platelet factor-4, angiostatin and thrombospondins, which mediate the suppression of
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tumor

growth

and

metastasis

through

negatively

(Sunderkotter et al., 1994) (O'Reilly et al., 1994).

regulating

angiogenesis

It was also speculated that,

through the collaboration with T-helper cells, the macrophages may present
tumor-associated antigens to induce an antitumor immune response.

Because of

their potential tumoricidal capabilities, TAMs have gained a lot of interests in the
development of novel macrophage-based antitumor therapies.
Despite these works that seem to lead to a conclusion that macrophages, if
appropriately activated, can prevent the establishment and proliferation of tumors, it
was observed as early as the 1980s that, macrophages may also support tumor growth
and dissemination (Steele et al., 1984).

Currently, there is an increasing consensus

on their pro-tumor role based on more and more research works on TAMs.

The

ambivalent relationship between macrophages and tumor cells suggests that the
tumor-associated macrophages have a high plasticity, and can function differently in
response to different signals within the tumor microenvironment. (Sica et al., 2007)
1.2. Macrophage classification and the heterogeneity of TAM phenotypes
According to the different phenotypes and distinct patterns of gene expression,
macrophages can be subdivided into type I and type II macrophages (Figure 1-1).
The type I macrophages (M1) have a phenotypic pattern of high interleukin-12
(IL-12), low IL-10, or low IL-4/-13. The propensity of M1 is often increased in
response to opsonized ligands and toll-like receptor (TLR) engagement.

Generally,

the typical type I macrophages play an indispensable role in both innate and acquired

3

immunity, and therefore they have a proinflammatory characteristic. They provide
an in-front defense line against different kinds of pathogens and malignant cells via
phagocytosis

and/or

induction

of

antibody-dependent

cellular

cytotoxicity.

Activated macrophages have the capability to recognize and bind to tumorigenic cells,
a process that lead to the subsequent lysis or phagocytosis of tumor cells.

As an

example, studies have showed that the amount of phosphatidylserine located in the
outer membrane leaflets is different between normal cells and tumor cells, and
macrophages can distinguish the differences thus recognize the tumor cells (Utsugi et
al., 1991) (Elnemr et al., 2000).

Figure 1-1. Polarization of macrophages.

However, the type II macrophages, or shortly M2, which have the
IL-10+/IL-12- phenotype, have an immunosuppressive characteristic.

Evidence

showed that TAMs can express typical M2 markers and have defective expression of
some proinflammatory cytokines, such as IL-12, tumor necrosis factor-alpha (TNF-α),
CC chemokine ligand 3 (CCL3), and IL-1 (Biswas et al., 2006) but high expression of
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IL-10 (Sica et al., 2000), hence the TAMs can be skewed to be M2.
IL-12, typically produced by macrophages, is a very important cytokine in
immune resistance against pathogens.

IL-12 is known as a T cell stimulating factor,

which can stimulate the growth and function of T cells. It can also facilitate the
production of IFN-γ and TNF-α and alleviate IL-4-mediated suppression of IFN-γ.
Therefore, lack of IL-12 production may result in dysfunction of macrophages’
antitumor responses.

It was observed that the expression of IL-12 gene is partially

controlled by members of nuclear factor-kappa B (NF-κB) family and failure to
produce IL-12 may be associated with defective activation of p50/p65 NF-κB in
TAMs (Sica et al., 2000).

This defective activation of NF-κB in TAMs also

correlates with impaired expression of NF-κB-dependent inflammatory functions, for
example, the expression of TNF-α, IL-1 and other cytotoxic mediators.

Moreover,

Ibe et al. proposed that high level production of IL-10 triggered by CCL2 or other
tumor-derived chemotactic factors (TDCFs) plays an important role in defective IL-12
production.

By interrupting the communication between tumor cells and their

stroma, TAMs could be switched towards IFN-γ production and tumor rejection (Ibe
et al., 2001).

Their observations also indicate that therapeutics targeted to block the

production of IL-10 as well as other immunosuppressive cytokines in tumor sites may
restore the antitumor functions of TAMs.
Interestingly, although TAMs have phenotypes similar to that of the
alternatively activated M2 macrophages, the properties of TAMs are intermediate

5

between those of proinflammatory (M1-like) and immunosuppressive (M2-like)
macrophages and more M2-polarized.

For example, TAMs can express high levels

of both M1 marker like nitric oxide synthase-2 (NOS2) and M2 marker like
arginase-1 (ARG1) simultaneously (Sica and Bronte, 2007).

The expression of

NOS2 and/or ARG1 can promote several metabolic reactions responsible for the
dysfunction of T cell responses, including the depletion of extracellular L-Arg, the
release of NO as well as increased production of reactive oxygen and nitrogen species.
Moreover, TAMs from murine fibrosarcoma, which usually show the M2-orientied
phenotypes, also express proinflammatory chemokines such as CXC chemokine
ligand 9 and 10 (CXCL9 and CXCL10), and CCL5 (Biswas et al., 2006).

It was

proposed in a dynamic model recently that during the tumor growth, there is a
dynamic change in the tumor microenvironment which could result in a gradually
switching of macrophage polarization, from M1 in the tumor initiation to M2 in the
established tumors (Sica et al., 2008). The functions of TAMs are controlled within
a functional spectrum with M1 and M2 being the two extremes.

Therefore, it is not

surprising that the TAMs are in between M1 and M2.
1.3. Macrophage polarization and M2-polarized TAMs
In response to different intercellular signals, macrophages can be polarized
into different phenotypes.

Recent works reviewed by Sica et al. (Sica et al., 2007)

suggested that the type I macrophages which have the antitumor activity are
differentiated

from

monocytes

exposed
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to

certain

factors

such

as

granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, LPS and some
bacterial products; whereas macrophage colony-stimulating factor (M-CSF),
IL-4/-13/-10 and some immunosuppressive agents trigger macrophages to
differentiate toward type II macrophages (Figure 1-2).

Among the factors that

induce the antitumor activity of macrophages, the IFN family, particularly IFN-γ, is
the most important one. Despite the lack of detailed knowledge of mechanisms by
which IFN mediate tumoricidal functions of macrophages, lots of in vitro, in vivo and
clinical studies have provided evidence to support the notion that IFN-inducible type I
macrophages have significant antitumor activity.

Figure 1-2. Cancer-induced polarization of macrophages.

An in vitro study showed that treatment of monocytes with IFN-γ alone or in
combination with TNF-α, GM-CSF or PPD, before/after co-cultured with tumor
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(HPC-4) cells, remarkably enhanced the de novo production of molecular factors
related to antitumor activity of macrophages (Baj-Krzyworzeka et al., 2004).

It has

also been reported that gene transfer of IFN-γ using adenoviral vector had negative
effects on tumor growth.

Urosevic et al. transferred the IFN-γ gene into 19 patients

with cutaneous lymphomas through injection of adenovirus-mediated IFN-γ
(Ad-IFN-γ) and performed transcriptional profiling on skin lesions obtained from the
patients before and after the treatment. The gene expression profiles revealed a
distinct gene expression signature in the lesions treated with Ad-IFN-γ.

The

productions of IFN-γ- and many of both type I IFN- and type II IFN- inducible genes
were detected in the lesions after treatment with Ad-IFN-γ (Urosevic et al., 2007).
The specific signaling mechanisms that may regulate macrophage polarization
have been partially identified.
transduction.

One of them is the NF-κB-mediated signal

The activation of NF-κB turns on the inflammatory repertoire of

macrophages, leading to the expression of proinflammatory cytokines (Karin and
Greten, 2005). Defective NF-κB activation could inhibit the transcription of some
key cytokines related to M1 phenotypes and the production of cytotoxic mediators.
For example, the impaired expression of NF-κB-induced inflammatory factors, such
as NO, TNF-α, IL-1, and IL-12, were observed in the TAMs isolated from tumors in
advanced stages (Sica et al., 2000).

Studies have also indicated that NF-κB is

activated in TAMs during the early stages of tumor initiation, but is largely suppressed
in established tumors (Saccani et al., 2006).
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As an important upstream component of

NF-κB activation, TLR/IL-1R signaling also plays a pivotal role in regulating
macrophage polarization (Karin et al., 2006).

Additionally, the Tie-2/Ang-2 pathway,

the TRIF/TBK1/IRF3 pathway, and hypoxia-induced pathway are reported to be
possible pathways in regulating the “shift” in macrophage phenotypes (Biswas et al.,
2008).

As more evidences emerge revealing the nature of the signaling in the

establishment of M2-like phenotypes of TAMs, the more and higher possibilities we
have to find the targets to reprogram them to express antitumor activities.
1.4. TAMs in the tumor microenvironment
TAMs are ‘educated’ into M2-like phenotypes by tumor-derived factors, such
as cytokines, growth factors, chemotactic molecules and proteases which may either
up-regulate or down-regulate the expression of macrophage effector molecules, thus
influence the functions of macrophages. Although it has been reported in many
studies that macrophages can promote tumor cytotoxicity and stimulate antitumor
lymphocytes by secreting a variety of molecular factors such as cytokines, their
cytotoxic activities may be largely suppressed in the tumor microenvironment.
Many tumor-derived molecules which can deactivate or suppress the cytotoxic
activity of activated TAMs, including IL-4, IL-6, IL-10, macrophage-derived
chemotactic factor (MDF), transforming growth factor beta1 (TGF-β1), prostaglandin
E2 (PGE2), and M-CSF, have been identified (Elgert et al., 1998).
As more and more studies related to TAMs unveiled their paradoxical roles
and functions on tumor cells, it is becoming obvious that multiple molecules play a
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pivotal role in the cross-talk between cancer cells and TAMs.

By transplanting

tumors into hosts with defective T cells or natural killer (NK) cells, Mantovani et al.
found that in many neoplasms the extent of macrophage infiltration and the number of
macrophages in tumor tissues are not mainly determined by specific immunity but by
the factors derived from cancer cells.

The key players in the regulation of

macrophage infiltration have been pointed to be monocyte chemotactic protein-1
(MCP-1/CCL2) and related CC chemokines (Nesbit et al., 2001).
In addition, another study has demonstrated that TAMs accumulation in
primary tumors is significantly correlated with the level of CCL2 expression and
tumor-derived chemotactic factors were found expressed by murine and human tumor
cells (Hoshino et al., 1995).

It has also been demonstrated that low level MCP-1

secretion led to tumor formation, while high level secretion resulted in marked tumor
necrosis with massive macrophage infiltration. To date, CCL2 has been shown to be
produced by a variety of human tumors, such as melanoma, malignant glioma,
ovarian cancer and meningioma. MCP-2 and MCP-3, also known as CCL8 and
CCL7, are the other two members of the CCL2 family which were isolated from
tumor cell lines.

In addition, breast carcinoma at advanced stage was reported to be

associated with increased expression of CCL5, and CCL5 receptor (CCR5) was
detected on TAMs.

It was suggested that CCL5 may play a role in macrophage

migration, tumor progression, and protumorigenic activity (Azenshtein et al., 2002).
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1.5. TAMs and angiogenesis
The early stage of tumor development is to induce blood vessel growth
(angiogenesis) by tumor cells, a fundamental step in the transition of tumors from a
dormant state to a malignant state.

Angiogenesis is considered to be the main

mechanism by which solid tumors can obtain nutrition supply for their proliferation
and metastasis.
TAMs are thought to be very important in several processes related to tumor
angiogenesis such as inflammation and tissue remodeling.

They can secret a vast

diversity of factors that promote angiogenesis including vascular endothelial growth
factor (VEGF), granulocyte colony-stimulating factor (GCSF), basic fibroblasts
growth factor (bFGF), insulin-like growth factor-I (IGF-I), platelet derived growth
factor (PDGF), transforming growth factor-β (TGF-β), tumor necrosis factor-α
(TNF-α), IL-1, IL-6, IL-8, substance P, prostaglandins and other kinds of monokines.
Experimental data demonstrated that neoplastic tissues showed angiogenic activity
only when macrophages were present (Mostafa et al., 1980).
A study based on flow cytometry analysis provided some evidence for the
relationship between tumor angiogenesis and macrophages.

By identifying and

quantifying the composition of infiltrating leukocytes in medullary and ductal breast
tumor tissues, the researchers showed that infiltrating leukocytes (macrophages in
particular) in medullary carcinoma are 3.2-fold more than those in ductal carcinoma.
This higher infiltration of macrophages was thought to be correlated with 3-fold
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enhanced endothelial expression of intercellular adhesion molecule-1 (ICAM-1), the
most important adhesion molecule for leukocyte extravasation (Reiss et al., 1998) in
medullary carcinoma (Bouma-ter Steege et al., 2004).

Simultaneously, a noticeable

overexpression of both VEGF-C and VEGF-D in ductal carcinomas was found.
From those observations, the authors suggested that the enhanced expression of
angiogenic factors in ductal carcinoma endothelial cells is responsible for the
suppression of ICAM-1 which in turn possibly down-regulate the levels of
macrophage infiltration.
Proteolytic enzymes, especially matrix metalloproteinases (MMPs), are also
key molecular factors in angiogenesis and mainly secreted by TAMs.

Although the

mechanisms by which MMPs secreted by TAMs enhance angiogenesis are not
completely understood, some key players have been identified.

During tumor

angiogenesis, tumor extracellular matrix is digested by MMPs to support rapid tumor
growth, invasion, and metastasis.

It is also reported that by mediating the

degradation of type IV collagen, MMP-9 can promote the migration and invasion of
both tumor cells and macrophages since tumor xenografts in MMP-9 knock-out mice
were smaller and contained fewer TAMs than wild-type counterparts (Huang et al.,
2002).
Up till now, different types of synthetic inhibitors against MMPs (MMPIs)
have been developed and put into clinical trials as anti-cancer therapeutics, but the
results of clinical trials turned out to be not very encouraging.
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However, this does

not diminish the importance of MMPs in the process of normal cell transformation to
malignant cells.

Details about MMPs, specifically when and how they take part in

the development of cancers are needed for more advanced application of MMPIs.
Moreover, TNF-α is largely produced by TAMs and is also a
hypoxia-inducible pro-angiogenic cytokines. TNF-α can initiate a cascade of signal
transductions upon its secretion, leading to the production of other factors which in
turn function positively on angiogenesis as well as other essential processes during
tumor development.

A TNF-α-dependent pathway to induce the expressions of

MMP-2 and MMP-9 in TAMs has been demonstrated recently.

Also, an increased

production of TNF-α was observed when macrophages were co-cultured with cancer
cells (Hagemann T., 2004).

Additionally, data from CSF-1 knock-out mice and

CSF-1 knock-down with antisence or RNAi all showed a reduced expression of
MMPs and VEGF.

When CSF-1 was re-introduced into the experimental system,

increased TAMs and accelerated tumor progression and metastasis were observed (Lin
et al., 2001).
TAMs may also have negative effects on tumor angiogenesis through the
production of factors such as thrombospondin 1 (TSP1) and GM-CSF.

These factors

in turn stimulate the production of the angiogenic protein plasminogen activator
inhibitor type 2 (PAI-2).
1.6. TAMs and hypoxia
Another phenomenon observed in tumor tissue is that TAMs are often found in
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the regions with low oxygen tension.

Hypoxia, a term used to describe the low

oxygen conditions (an oxygen tension of 0.1%-0.5%), usually occurs more than
100μm from blood vessels in tumor microenvironment.

Besides being regulated by

cytokines, the localization of TAMs is also, likely to a large extent, regulated by
hypoxia.
Hypoxic conditions in tumor tissues can induce the expression of all three
endothelial cell adhesion molecules necessary for monocytes extravasation, among
which VEGF is the important hypoxia-induced genes and is also the most extensively
studied.

The VEGF-R1/flt-1 on monocytes can be activated by binding of VEGF.

A positive correlation between elevated VEGF expression and increased macrophage
infiltration has been observed in breast cancer (Leek et al., 2000). In addition to its
chemoattractic activity on macrophages, VEGF also has a pro-angiogenic activity.
The expression of VEGF is induced by hypoxia via the expression of
hypoxia-inducible factor-1 alpha (HIF-1α).

CXCR4, a receptor for CXC chemokine

SDF-1/CXCL12, is also evidenced to be up-regulated in macrophages by hypoxia
through HIF-dependent pathway (Schioppa et al., 2003).

A possible alternative

mechanism for recruiting macrophages to the hypoxic areas in tumors was proposed
based on the observation that macrophages accumulated in the regions where
endothelial monocyte activating peptide II (EMAP II) was highly expressed.
Surprisingly, some factors involved in macrophage migration such as CCR5
are down-regulated by hypoxia, as mentioned above.
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Therefore, it is suggested that

hypoxia can, on one hand, induce the expression of chemoattractants which are
responsible for macrophage localization in hypoxic regions; on the other hand, it can
inhibit other molecular factors that may attract macrophages/monocytes randomly
into tumor sites.

In line with this assumption, Grimshaw et al. found that hypoxic

macrophages can up-regulate the expression of mitogen-activated protein kinase
(MAPK) phosphatase-1 (MKP-1), an enzyme that can dephosphorylate ERK1/2 and
p38 MAPK, thus hypoxia indirectly inhibits MCP-1-induced macrophage migration
which requires the phosphorylation of p38 MAPK and ERK1/2 (Grimshaw and
Balkwill, 2001).
Hypoxia-inducible factor is a heterodimeric transcription factor that can
initiate the expression of a broad range of genes involved in angiogenesis, cell cycle
control as well as apoptosis.

Fully activated HIF factor contains both of its two

subunits: one is alpha subunit which can be degraded by oxygen-requiring enzymes
under normal oxygen condition and the other is a constitutively expressed beta
subunit.

Hypoxia results in the accumulation of HIF alpha subunit, allowing its

activation of downstream genes.

An in vivo study provided the evidence that tumor

xenografts produced from HIF-1α-/- embryonic stem cells and HIF-1β-deficient
fibroblasts had poor vascularization and reduced rate of growth in nude mice
compared with the wide-type counterparts (Maxwell et al., 1997).
Some key effector molecules in angiogenesis secreted by TAMs are also
regulated by hypoxia. MMP-1 and MMP-7 are hypoxia-inducible MMPs secreted
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by TAMs, and MMP-1 has been identified as being regulated by HIF-2α (Petrella et
al., 2005). TAMs, angiogenesis, and hypoxia are highly related and are essential for
tumor growth and expansion.
1.7. Conclusion of TAMs
Differentiated mature TAMs are similar to M2 macrophages both
phenotypically and functionally.

TAMs, which preferentially express M2-associated

genes, promote tumor progression by secreting cytokines that promote tumor growth,
favoring angiogenesis and/or lymphenogenesis, favoring tumor-induced ECM
remodeling, and tuning of adaptive immunity. However, they can also express genes
associated with classical M1 macrophages such as IFN-inducible M1 chemokines:
CXCL9, CXCL10 and CXCL6.

IFN-inducible chemokines generally have

potentially antitumor activities, as many of such chemokines are inhibitors of
angiogenesis and chemoattractant of cytotoxic T cells.

As a unique cell population

within tumor microenvironment, the cytotoxic activities of TAMs are often
suppressed and susceptibility to IFN-γ/LPS mediated stimulation is reduced.

The

mechanisms behind the paradoxical effects of TAMs on tumors have been extensively
studied and some clues have gradually emerged.
The cross-talk between cancer cells and macrophages which can influence
TAM phenotypes is very important during tumor development.

The mechanisms

governing the interaction between macrophages and tumor cells are extensively
studied.

One of the mechanisms proposed was that immunosuppressive activities of
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tumor might be regulated by overexpression of those immunosuppressive factors.
The major contributors identified by far are PEG2, M-CSF, TGF-β1, IL-4, IL-6 as
well as IL-10.
2. Interferons (IFNs)
2.1. Introduction of IFNs
It has been fifty years since the first description of interferon by Alick Isaacs
and Jean Lindemann.

In their landmark study, they found that a factor, named

“interferon” by them thereafter, was released following incubation of heated virus
with chick chorioallantoic egg membranes; and this factor can inhibit viral replication
in infected cells.

Since then, different viral-induced IFNs have been discovered and

their antiviral activities have been studied. In 1969, Gresser et al. reported that
tumor growth was inhibited in animals after treatment with IFN (Gresser et al., 1969).
However, the IFN preparations used in those studies were not pure so that the
discoveries with regard to the antitumor properties of IFNs were not completely
convincing. It was not until 1980 when cloning of IFNs became a possibility that the
research on IFNs entered into a new era and has made a great progress (Taniguchi et
al., 1980).
2.2. Classification of IFNs
Various pathogen-associated molecules, such as bacterial LPS, unmethylated
CpG DNA, and viral double-stranded RNAs, can elicit a series of reactions leading to
innate immune response in host.

These reactions result in the production of various
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cytokines such as IFN-α and IFN-β, which belong to type I IFNs and are vital
cytokines in the operation of adaptive immunity.

Besides the two key cytokines

IFN-α and IFN-β that are most extensively studied, type I IFNs also include IFN-ω,
IFN-ε and IFN-κ.

All of the members in type I IFN family can bind to a specific cell

surface receptor, the IFN-α receptor (IFNAR), in both autocrine and paracrine
manners to exert multiple biological functions including the activation of antiviral
defense, modulation of the immune system, and host defense against tumors.

In the

human genome, type I IFN family contains three subtype genes: thirteen IFN-α genes,
one IFN-β gene and two IFN-ε genes.
There are other two major classes of IFNs, type II IFNs and type III IFNs
based on sequences, chromosomal locations, and receptor specificities.
The only member of human type II interferon is IFN-γ, a dimeric soluble
cytokine originally called macrophage-activating factor. Unlike type I IFNs which
are induced by viruses, the production of type II IFNs, mostly by lymphocytes, is
stimulated by different immune stimuli, such as mitogens, antilymphocytic serum and
antigens.

IFN-γ initiates the signal transductions through a different receptor

composed of IFNGR-1 and IFNGR-2 subunits. The single copy of IFN-γ gene is
located on chromosome 12.
The newly discovered human type III IFNs encoded by genes on chromosome
19 consist of three members: IFN-λ1, IFN-λ2 and IFN-λ3, also known as IL-29,
IL-28A and IL-28B, respectively (Kotenko et al., 2003). Structural and functional
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characterization of the IFN-λ1 and IFN-λ3 gene promoters revealed their similarities
to IFN-β and IFN-α genes, respectively.
A recent study has shown that both antiviral type I and type III IFN genes can
be activated by viral infection/replication via TLR-dependent and -independent
pathways (Sheppard et al., 2003), but type III IFNs bind to a distinct membrane
receptor composed of IFNLR1 and IL10R2.

Notably, the IFNLR1 is specific to type

III IFNs, whereas the IL10R2 subunit can also interact with IL-10, IL-22 and IL-26.
Despite their diverse structural and functional properties, the three classes of
IFNs have several effects in common, such as (1) they have antiviral and
antioncogenic properties; and (2) they can activate macrophages and NK cells to
present foreign epitopes to T cells.
2.3. IFN functions
IFNs are central regulatory mediators of the immune system. They can be
produced by different types of immune cells in response to a wide range of foreign
agents, such as viruses, parasites, and tumor cells.

Major activities of IFNs include

immunomodulating activities, antiviral effects, and antitumor activities.

At the

molecular level, IFNs exert their modulatory functions through many mechanisms
such as (1) activation of macrophages and other lymphocytes, and (2) enhancement of
the expressions of major histocompatibility complex (MHC) class I and II antigens
and tumor-associated surface antigens, thus increasing the presentation of peptides to
T cells.
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As an extraordinarily well studied case among various functions of IFNs,
nearly all types of IFNs are important in fighting against RNA virus infection. IFNs
act on target cells to establish an antiviral state in the cells which has influences on
various phases of viral infection, including virus entry, transcription, RNA stability,
translation, maturation, assembly as well as release.

One of the mechanisms by

which dsRNA-induced IFNs fight against viruses has been well established.

RNase

L is an IFN-inducible ribonuclease which, upon activation, destroys all RNA within
the cell.

The type I IFNs induced by viral RNA stimulate the expression of

2’-5’-linked oligoadenylate by activating an enzyme called 2’-5’ oligoadenylate
synthetase, which in turn can activate RNase L to degrade viral RNA as well as
cellular RNA.

Interestedly, this IFN-inducible enzyme, RNase L, has also been

reported to be associated with prostate cancer.

For example, one of the studies

showed that RNASEL gene (the gene that encodes RNase L) mutations and some
variants allow tumor cells to escape a potent apoptotic pathway (Xiang et al., 2003),
which supports the possible tumor suppressor role of RNase L as well as IFNs. This
study also provided the possibility that there is a link between IFN-induced antiviral
immunity and antitumor activities.
Indeed, the antitumor activity of IFNs, manifested on their inhibition of
malignant cell growth, has long been documented (Sen and Lengyel, 1992).

Studies

showed that both type I and type II IFNs can induce the expression of the
promyelocytic leukemia (PML) gene (Heuser et al., 1998), which is involved in
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haematopoietic differentiation and in the control of cell growth and tumorigenesis
presumably by encoding a putative tumor suppressor protein involved in the control of
apoptosis (Rego et al., 2001).
Particularly, because of their essential role in the induction of apoptosis in
cancer cells,

IFN-α and IFN-β (IFN-α/β) are sometimes referred to as ‘negative

growth factors’ (Pestka et al., 1987) (Gresser and Belardelli, 2002). However, the
molecular mechanism of their tumor suppression activity is still unknown. Recently,
it was reported that there is a link between IFN-α/β signaling and the responses of
tumor suppressor p53. It is well known that p53 can induce cell cycle arrest or
apoptosis once it is activated in response to DNA damage, playing a central role in
tumor suppression (Vousden and Lu, 2002).

The study carried out by Takaoka et al.

showed IFN-α/β can induce the transcription of p53 gene, as shown by an increase in
the level of p53 protein which contributes to tumor suppression (Takaoka et al., 2003).
Besides direct actions on malignant cells, the IFNs can also stimulate
immune-mediated antitumor activity through mediator cells.

IFN-γ, originally

known as the macrophage-activating factor, orchestrates a variety of cellular programs
in the macrophages through transcriptional regulation of immunologically relevant
genes.

Macrophages stimulated by IFN-γ induce direct antimicrobial and/or

antitumor activity with enhanced antigen processing and presentation capacities. It
is also highly possible that IFN-γ, both directly and indirectly, initiates a cascade of
signaling involved in the production of other types of IFNs and IFN-inducible genes,
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priming the macrophages’ antitumor activity (Schroder et al., 2004).
As potential antitumor drugs, IFNs have been tested in many clinical trials.
IFN-α has already been approved to be used in the treatment of hairy cell leukemia in
1985.

Recombinant IFNs were found to have therapeutic potentials in other

malignancies, such as chronic myelogenous leukemia (CML), B and T cell
lymphomas, melanomas, and Kaposi’s sarcoma (Borden, 2005).
3. Interferon regulatory factors (IRFs)
3.1. Introduction of IRFs
Studies on mechanisms of IFNs induction by viruses and dsRNA led to the
discovery of a family of transcription factors involved in the regulation of IFN genes,
termed interferon regulatory factors (IRFs). Actually, the expression of IFN genes is
primarily regulated at the transcription level which made the IRF family of
transcription factors the focus of researches.
The IRF family is a group of transcription factors that play very important
roles in regulating the expressions of IFN genes as well as IFN-inducible genes (also
known as IFN-stimulated genes, ISGs).

From the induction of IFNs to diverse IFN

responses, the IRF family is a focal point of the entire IFN system.

They are also

involved in the establishment and execution of innate and adaptive immunity,
modulating the development of the immune system.

Furthermore, they can regulate

the growth and/or differentiation of many cell types, and accordingly play a pivotal
role in leukemia and other cancers.

22

To date, the IRF family includes nine members (IRF-1 to IRF-9), all of which
can bind to IFN-stimulated response element (ISRE) (Taniguchi et al., 2001).
Generally, the IRF family members have significant homology in the
N-terminal 115 amino acids which contains a DNA binding domain (DBD).

This

DBD is featured by having a unique “tryptophan cluster” DNA-binding region of five
tryptophan residues, which has an α/β architecture consisting of a cluster of three
α-helices (Helix 1, Helix 2 and Helix 3) flanked by a four-stranded β-sheet on one
side (Figure 1-3) (Escalante et al., 1998).

The IRF molecules may bind DNA either

as a monomer or a dimmer depending on their subtypes.

The protein monomer

binds DNA with a helix-turn-helix (HTH) motif in which three of the five conserved
tryptophan residues are in contact with DNA. The HTH motif is composed of Helix
2 and Helix 3 of the three α-helices in the DNA-binding region with the Helix 3 lying
in the DNA major grove.

A ‘GAAA’ core sequence within a 13bp DNA element in

the IFN promoter, known as ISRE, contacts with Helix 3 of the HTH motif. There is
another important regulatory domain on the C-termini of IRFs: IRF association
domain (IAD) which is conserved in all IRFs from IRF-3 to IRF-9 but not in IRF-1
and IRF-2. Structural analyses of the C-terminal regulatory region on IRF-4 and
IRF-8 revealed that the C-terminal IAD is composed of a β-sandwich core flanked by
helices and loops.

The IAD crystal structure also demonstrated that the

auto-inhibitory mechanism for IRF-3 and IRF-7 is due to an interaction between H1
and H5 helices prior to stimulation.
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Figure 1-3.

Crystal structure of DBD of IRF1. Helix 1, Helix 2 and Helix 3 are

shown in blue, green and orange, respectively.

‘GAAA’ core sequence as well as

pairing ‘TTTC’ are shown in cyan, whereas the remainder of DNA is shown in purple.
Three conserved tryptophans that make contacts with DNA are shown.

(PDB

ID:1IF1)

It is often observed that IFNs exert their functions in concert with other
transcription regulators such as NF-κB. As early as 1989, the NF-κB was identified
as a critical transcription factor involved in the IFN-β genes regulation (Lenardo et al.,
1989).

Actually, the stimulation of the transcription of IFN-β genes by viruses or

dsRNA is modulated by an enhanceosome composed of IRFs, NF-κB, activating
transcription factor (Maxwell et al., 1997)-2 and c-Jun heterodimer, and the high
mobility group protein HMG I(Y). The enhanceosome can further bind with histone
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acetyl transferases and the CREB binding protein (CBP) (Kim and Maniatis, 1997).
The assembly of IFN-β enhanceosome is a prerequisite for efficient transcription of
IFN-β genes (Kim et al., 1998). However, the ISREs of IFN-α gene promoters do
not contain any NF-κB site, but have multiple 'AANNGAAA' repeats which can be
bound by members of IRF family.

For example, IRF-1, IRF-3 and IRF-7 together

with histone transacetylases can form the transcriptionally active IFN-α gene
enhanceosome (Au et al., 2001). Therefore, IRFs are very important and required
for transcriptional activity of type I IFN genes.
3.2. Regulations of IRF activities
IRF activities are modulated by a variety of post-translational modifications
such as phosphorylation, acetylation, ubiquitination, and proteasome-dependent
degradation.

In the induction of type I IFNs, phosphorylation is the main event to

regulate the signaling pathways. It has been discovered that IFN responses depend
on kinases of the Janus kinase (JAK) and mitogen-activated protein kinase (MAPK)
families that phosphorylate signal transducers and activators of transcription (STAT)
proteins (Platanias, 2005).

But the phosphorylation of IRFs is more likely to be

modulated by other kinases.

For example, the phosphorylation of IRF-3 and IRF-7

by TBK-1 and IKKε is a prerequisite of IFN induction in the TLR-mediated pathway
(Solis et al., 2006).

However, it has not been fully explored if phosphorylation is a

necessary step for IRF activation and translocation.
Acetylation of IRFs in vivo and in vitro can cause an alteration of DNA
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binding and transcriptional activities.

For example, IRF-2 and IRF-7 can be

acetylated by histone acetylases GCN/PCAF and CBP/p300 at the lysine residues
flanking tryptophan in the DBD.

Although both residues are conserved throughout

the IRF family, not all IRF family members are acetylated in similar conditions,
suggesting that the acetylation of IRFs is selective.
IRFs are degraded by proteasome through the ubiquitin pathway.

It has

already been found that some viral proteins can degrade IRF-3 and IRF-7 to impair
the induction of IFNs.

As a matter of fact, the destabilization of IRFs is a normal

process in regulating IRFs activities. Saitoh et al. demonstrated that upon interaction
with the peptidylprolyl isomerase Pin1, IRF-3 changes the isomerization status which
leads to a rapid destabilization of IRF-3. Poly-ubiquitination of IRFs linked through
lysine 48 of ubiquitin is a common mark for IRF degradation.

Strikingly, it was

shown that mono-, multi- or poly-ubiquitination through lysine 63 rather than lysine
48 of ubiquitin can enhance transcription-initiating activities IRFs.

One study

showed that ubiquitination of IRF-7 upon TLR stimulation through an E3 ubiquitin
ligase, TNF receptor-associated factor 6 (TRAF-6), resulted in increased IFN gene
transcription (Kawai et al., 2004).
3.3. IRF-1
IRF-1, identified in 1988 in Taniguchi’s lab, is the founding member of the
IRF family and is also the one most extensively studied at the molecular level.

It

was isolated as a DNA-binding protein due to its affinity to a specific DNA sequence,
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termed positive regulatory domain I (PRDI) element, in the IFN-β promoter
(Miyamoto et al., 1988).
localized in the nucleus.

The IRF-1 protein is constitutively expressed and is
It has two consensus nuclear localization signals (NLS) to

mediate its nuclear translocation.

Between amino acid 185 and 256 on IRF-1

molecule, there are two transcription activator fragments which are enhanced by a
C-terminal fragment that does not have activator function per se.

The N-terminal

contains a 60 amino acids domain which can strongly inhibit the transcriptional
activity of IRF-1.

This repression domain exits in most, if not all, of the members of

IRF family identified so far.
IRF-1 mRNA is expressed at a basal level in nearly all the cell types examined
except early embryonic cells (Kroger et al., 2002).

Transcription of IRF-1 mRNA

can be induced by many factors including IFNs, dsRNA, certain cytokines and some
hormones.

Among those inducers, IFN-γ is the strongest one known by far.

Additionally, certain combinations, for example IFN-γ and TNF-α, can elicit even
higher level of IRF-1 mRNA expression.

On the other hand, some molecular factors,

such as IL-4, can inhibit the expression of IRF-1 (Ohmori and Hamilton, 1997).
The ability to activate transcription of target genes through binding specific
promoters is the most important activity of IRF-1.

The IRF-1 binding sequence is

identified to be 5’-G(A)AAA(G/C)(T/C)GAAA(G/C)(T/C)-3’, which is contained in
the promoters of many ISGs.

On the molecular level, IRF-1 can be considered as a

typical modular molecule of which the distinct protein domains mediate different
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molecular actions.

Similar to other IRF-family members, the DNA-binding domain

(DBD) is mapped to the 125 amino acids at the N-terminal of IRF-1 protein. As
mentioned before, this DBD is characterized to be a HTH motif with five tryptophan
repeats.

Indeed, as revealed by the crystal structure of IRF-1 bound to PRDI DNA

element in the IFN-β promoter, this HTH motif of IRF1 exemplifies the HTH motif of
IRF family which binds DNA through three of the five conserved tryptophans
(Escalante et al., 1998).
Interestingly, by activating the IRF-2 promoter, IRF-1 also induces the
expression and accumulation of IRF-2 which can inhibit the transcription of
IRF-1-inducible genes (Harada et al., 1994).

Through this negative feedback loop,

IRF-1 and its antagonist IRF-2 have been identified as regulators of type I IFN and
type I IFN-inducible genes. Moreover, mRNA levels of both IRF-1 and IRF-2 are
found to be regulated by cell cycle through an unclear mechanism.

The reciprocal

regulation between IRF-1 and IRF-2 has been shown to have impact on tumor
progression.

Harada et al. overexpressed IRF-2 in NIH 3T3 cells and injected some

of the IRF-2-overexpressing cell clones subcutaneously into nude mice.

After 2 to 3

weeks, tumors emerged in those mice and continued to grow vigorously, but no
tumors developed in mice injected with untreated NIH 3T3 cells. The tumorigenic
activity of IRF-2 was suppressed after increasing the expression of IRF-1 in the same
clones by cotransfection of another plasmid carrying IRF-1 gene.

It was also

suggested in their study that a transient decrease of the IRF-2/IRF-1 ratio might be a
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key point in the regulation of cell growth by IFNs (Harada et al., 1993).
Some IRF-1-induced transcriptions require the interaction of IRF-1 with other
transcription factors.

IRF-1 can regulate the expression of inducible nitric oxide

synthase (iNOS), and in macrophages, the induction of iNOS can catalyze the reaction
of transient production of nitric oxide (NO) which is one of the contributors of
macrophage cytotoxicity to tumor cells. The production of NO is induced by the
interaction between IRF-1 and NF-κB through the iNOS promoter, to defend against
bacterial infection and to facilitate the elimination of tumor cells.

The iNOS

promoter can also be activated by combined action of IFN-γ with IRF-1 or NF-κB.
In addition, it has been reported that IRF-1 can cooperate with p53, the tumor
suppressor, to induce the transcription of p21WAF/CIP1, an important regulator of
cell cycle progression (Tanaka et al., 1996). It can also form a protein complex with
some histone acetylases, CREB binding protein (CBP) for instance.
The activity of IRF-1 is regulated through many different ways by various
factors.

Phosphorylation, a common way to regulate many transcription factors, is

one of the best studied regulations of IRF-1.

Bioinformatic and biochemical analysis

showed that the IRF-1 protein can be phosphorylated on serine/threonine at multiple
sites, but whether IRF-1 requires phosphorylation to fulfill its function is still
unknown.

The oncogenic transcription factor IRF-2 can prevent certain promoters

from being activated by IRF-1, possibly through competing with IRF-1 to bind to the
same DNA-binding site.

IRF-8, another functional antagonist of IRF-1, has the
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ability to suppress the IRF-1 induced activation of ISRE-associated genes.

The

inhibitory activity of IRF-8 on IRF-1 is modulated on two key levels: one is that
IRF-8 is expressed specifically in lymphoid, whereas IRF-1 is extensively expressed;
the other is when certain tyrosines of IRF-8 are phosphorylated, its DNA-binding
activity but not its association with IRF-1 is inhibited, thus it facilitates
heterodimerization of IRF-8 and IRF-1 and also enhances DNA binding of the whole
complex (Sharf et al., 1997).
Detailed studies suggest that IRF-1 plays a role in host defense against
pathogens, tumor suppression, and development of the immune system by inducing
downstream genes involved in immunomodulation, antiviral effects, and antitumor
effects.

It has been shown that the overexpression of IRF-1 in different cell types

from mammalian species resulted in growth inhibition (Mario Koster, 1995).
can act as a tumor suppressor.

IRF-1

The role of IRF-1 in tumor suppression and immune

response can be described from several aspects.

One of the important events during

DNA damage induced apoptosis of mitogen-activated T lymphocytes is the
production of Fas ligand which binds to Fas receptor on cell membrane to induce
apoptosis by initiating a series of signal transduction.

In addition, Fas/FasL system

also plays a role in the apoptosis of cytotoxic T-cell targeted cells.

Studies

employing different methodologies, including deletion and mutagenesis of an IRF-1
binding site in FasL promoter, overexpression of IRF-1, and down-regulation of IRF-1
activity by antisense RNA, suggest that the FasL expression in activated T cells is
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regulated by IRF-1 (Chow et al., 2000). Moreover, some members of the caspase
family, such as caspase-1 and caspase-7, were investigated to be transcriptionally
induced by IRF-1.

The caspase family is an essential component in the signaling

pathways to induce apoptosis.

Cytokine is another inducer of apoptosis, and IRF-1

seems to be an important mediator in initiation of apoptosis by certain cytokines.
IFN-γ, for example, can induce cell cycle arrest and p53-independent apoptosis in
primary cultured hepatocytes, however, hepatocytes from IRF-1-deficient mice were
completely resistant to IFN-γ-induced apoptosis.

It was proposed that IRF-1

mediates the IFN-γ signaling in primary hepatocytes, regulating cell cycle arrest via
p53 expression and apoptosis (Kano et al., 1999).

Northern blot analysis showed

that IFN-γ-induced p53 mRNA expression but not constitutive p53 mRNA expression
was regulated by IRF-1.

Furthermore, gene expression profiling demonstrated that

except for a few detectable amount of caspase-1 in IRF-1 deficient mice, Fas,
caspase-3, or caspase-11 did not change in between wild type and IRF-1-deficient
hepatocytes.
As mentioned previously, IL-12 is a key cytokine in linking innate and
acquired immune responses, allowing phagocytes to facilitate the development of
cell-mediated immunity to a variety of pathogens as well as tumor cells.

IL-12 has

been characterized for its ability to induce IFN-γ secretion from T cells and NK cells
directly.

To elucidate the potential ability of IRF family members in the regulation

of IL-12, IL-12 mRNA and protein levels in LPS and/or IFN-γ-activated macrophages
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from IRF-1-/- and IRF-2-/- mice were examined.

Results from this study indicate that

loss of IRF-1 leads to impaired production of not only IL-12 p40 but also IL-12 p35
mRNA after treatment with LPS or LPS plus IFN-γ (Salkowski et al., 1999).
Therefore, not only does IRF-1 have the properties to repress tumor growth, but also
has the function to facilitate immune response to fight against tumors.
3.4. IRF-3
Another member in IRF family, IRF-3, also plays a critical role in regulation
of innate immunity and has potential activities in regulating macrophages to kill
tumor cells.

Unlike IRF-1 whose production is induced by viral infection and

cytokines, IRF-3 is constitutively expressed in the cells.

Recent studies have

identified that IRF-3 is a key regulator of type I IFN genes with its active form
induced by pathogens (Alexopoulou et al., 2001).

IRF-3 is initially found

accumulated in the cytoplasm with an inactive form.

ISG15 is an IFN-induced

ubiquitin-like protein which can interfere with ubiquitin-mediated degradation of
IRF-3, thus stabilize IRF-3 in the cells (Okumura et al., 2008).

Upon stimulation by

LPS, dsRNA or viral infection, IRF-3 is post-translationally activated by TLR
signaling, and after being phosphorylated on serine/threonine, it forms a complex with
CBP/p300.

Then, this complex translocates into the nucleus and activates the

transcription of IFN-α/β, as well as other ISGs.
Structural and functional analyses have revealed that phosphorylation-induced
IRF-3 dimerization generates an extensive acidic pocket with responsibility for
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binding with CBP/p300. Based on the crystal structure of C-terminal regulatory
domain of IRF-3 (residues 175−427), named as IRF-3 175C, and mutational analyses
of IRF-3, it was proposed that the phosphorylation-induced dimerization is the
activation mechanism of IRF-3 (Takahasi et al., 2003).

Ser385 or Ser386 (2S site) is

a part of the unique phosphorylation site of the Ser-Ser-Leu motif (SSL motif) in
IRF-3 gene.

Mutagenesis of the serine residue in the 2S site to alanine abolished the

phosphorylation and dimerization of IRF-3.

Meanwhile, an observation showed that

mutation of the serine and threonine residues between residues 395 and 407, termed
as 5ST site, to phosphomimetic aspartate (IRF-3 5D) can result in constitutively active
IRF-3 (Lin et al., 1999).

This super active IRF-3 is a strong activator of promoters

containing ISRE regulatory elements or PRDI-PRDIII.

This observation supported

an autoinhibition model proposed by Hiscott et al. that two regions of IRF-3,
corresponding to residues 380−427 (serine-rich region) and 98−240, are interactional
to form a closed structure in an inactive state that is opened by the introduction of
massive negative charges by multiple phosphorylation.
Besides the stimulation of IRF-3 by TLR, IRF-3 and its targeted IFN genes
can also be activated by bacteria like Listeria monocytogenes through a TLR- and
Nod2-independent pathway.

Scientists in Max F. Perutz’s Laboratory investigated

the signals and molecules associated with the synthesis of IFN, and also the response
to IFN by mouse macrophages infected with Listeria monocytogenes.

They

observed that the synthesis of type I IFNs, expression of a subset of IFN-induced
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genes, and the biological response to type I IFNs were lost upon IFN-β deficiency.
Based on these observations, they demonstrated that IFN-β is the critical
immediate-early IFNs made during infection. And they further identified that the
induction of IFN-β is absolutely dependent on the presence of IRF-3 (Stockinger et al.,
2004).
From the studies on the mechanisms of the pathogen induced innate antiviral
response, scientists found that these responses are almost all lead to the activation of
IRF-3 and IRF-7.
IRF-3 and IRF-7.
cytoplasmic

As mentioned above, the TLR is essential in the induction of
Double-stranded RNA can be recognized by TLR-3 or

helicases

retinoid-inducible

gene-1

(RIG-1)

and

melanoma

differentiation-associated gene-5 (MDA-5) which are characterized by the presence of
caspase recruitment domains (Rego et al., 2001) (Kato et al., 2006).

The

downstream signaling pathways of TLR-3 or RIG-1/MDA-5 lead to the
phosphorylation of IRF-3 by two kinases: TBK-1 and IKKε.
phosphorylation is serine 386 at the C-terminal region.

The key residue of
Alternative pathway

mediated by TLR-4 can also lead to the phosphorylation of IRF-3, wherein TLR-4
triggers the myeloid differentiation primary response gene 88 (MyD88)-independent,
TIR-domain-containing adaptor-inducing IFN-β (TRIF)-dependent pathway via
TRIF-related adaptor molecule (TRAM) to induce type I IFNs.

TRAF-6, RIP-1 and

TRIF can trigger the phosphorylation of IRF-3 by TBK-1 and IKKi, resulting in the
translocation of IRF-3 to the nucleus where it induces the expression of IFN-β and
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IFN-inducible genes.
After phosphorylation, IRF-3 then homodimerizes or heterodimerizes with
IRF-7, another important interferon regulatory factor largely restricted to lymphoid
tissue, and translocates to nucleus where it associates with the CRFB binding protein
CBP/p300 (Lin et al., 1998).

Notably, the activation of IRF-3 alone is sufficient to

induce type I IFNs and initiate the type I IFNs-associated immune responses.
3.5. IRF-7
At first, IRF-7 was considered as a factor binding to the Qp promoter of the
Epsin-Barr Virus (EBV) based on previous studies (Pagano, 1997). Thereafter, it
was identified that a splice variant of IRF-7 was a critical factor in the induction of
IFN-α genes (Au et al., 1998).

It shares most of IRF-3 activities and is activated in

an IRF-3 dependent pathway.
Not only type I IFNs but also TNF-α can activate the expression of IRF-7,
which can be observed in plasmacytoid dendritic cells where the production of TNF-α
is high due to TLR-7/-8 and TLR-9 action.
the important function of IRF-7.

Gene knockout study has clearly showed

Kenya Honda et al. used mice deficient in the

IRF-7 gene to show the essential role of IRF-7 in the induction of IFN-α/β (Honda et
al., 2005).

They generated IRF7-/- mice and then collected mouse embryonic

fibroblasts (MEFs) from three distinct viruses infected IRF7-/- mice.

As revealed by

quantitative RT-PCR, IFN-α/β mRNA was markedly reduced in IRF7-/- mice.

In

contrast, MEFs from MyD88-/- mice retained the ability to induce IFN-α/β mRNAs in
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response to virus infection. The study clearly showed that IRF-7 is essential for the
activation

of

type

I

IFNs

via

two

different

pathways:

virus-activated,

MyD88-independent pathway and the TLR-activated, MyD88-dependent pathway.
It also demonstrated that a decreased serum IFN levels was correlated with IRF-7,
indicating the importance of the IRF-7-dependent induction of systemic IFN
responses for innate antiviral immunity.

Also, IRF-7 is activated in its

phosphorylated form and the key residues for phosphorylation of IRF-7 by
TBK-1/IKKε are serine 477 and 479.

However, TLR-7 and TLR-9 stimulated

phosphorylation of IRF-7 depends on MyD88 and IĸB.
IRF-3 and IRF-7 are early IRFs, among the nine mammalian IRFs, activated
by TLR and other types of signal factors that play a very important role in the initial
induction of type I IFNs.

Previous studies also showed that the complex of IRF-3

homodimer and coactivator CBP/p300 is responsible for the primary activation of
IFN-α/β gene.

Then, the secreted IFN-α/β subsequently induces IRF-7 expression,

which has a role in the secondary amplification of IFN-α/β gene expression in a
phosphorylation-dependent manner (Honda and Taniguchi, 2006).

It is noteworthy

that the C-terminal regulatory domain RD and serine-rich region (SRR) are conserved
between IRF-3 and IRF-7 and these proteins share functional similarity (Takahasi et
al., 2003).
3.6. Other members of IRF family
Besides the members of IRF family discussed above in details, other members
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are also very important in the immune system. The IRF family plays a role in
directing the development of innate and adaptive immunity, which can be
demonstrated by the activity of IRF-4 and IRF-8 (Eisenbeis et al., 1995) (Politis et al.,
1992).

Both of them are only expressed in immune cells. They can not only bind

the common binding site of the IRF family, ISRE, but also bind various Ets/IRF
composite elements through their interaction with PU.1.

Due to the activity of IRF-8,

the production of IFNs is much higher in dendritic cells than in other cells.
IRF-5 plays a role in the induction of type I IFNs as well as proinflammatory
cytokine production. It can be activated by TLR signaling. For example, TLR-4
can trigger the MyD88-dependent pathway which induces the formation of a complex
that consists of TRAF-6, IL-1-receptor-associated kinases (IRAKs) and IRF-5. The
complex can further lead to the activation and translocation of NF-κB, AP-1 and
IRF-5, resulting in the production of proinflammatory cytokines.

Like IRF-3 and

IRF-7, IRF-5 can be phosphorylated by TBK1/IKKε, but this phosphorylation only
can not lead to its activation. It is also reported that IRF-5 has a role in apoptosis
and the immune response to pathogens.

Another member IRF-6 is a vital regulator

in determining the keratinocyte proliferation-differentiation switch (Richardson et al.,
2006).
Following type I IFN-receptor interaction, a latent cytoplasmic IRF-9 complex
with STAT1 and STAT2 through the activation of the JAK/STAT pathway, binds to the
ISRE, and stimulates transcription of a large set of IFN-stimulated genes.
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The

STAT1, STAT2 and IRF-9 complex is thought to be a typical type I IFN transcription
factor, nevertheless, it is identified that it is also involved in the IFN-γ signaling
pathway (Matsumoto et al., 1999).
The IRF family members play critical multifunctional roles throughout the
immune system.

They are involved in various signaling pathways, and some of the

members are potent mediators regulating the antitumoral immune responses.

It

holds a great promising to the anti-cancer strategies by targeting on IRF family
members.
4. Adenoviral vectors
Gene therapy is a promising tool to treat or prevent diseases. Based on the
cargo gene to be delivered, gene therapy can be largely categorized into three types:
(1) replacing a mutated gene that causes disease with a healthy copy, (2) inactivating a
mutated gene that is functioning improperly, and (3) introducing a new gene into the
body to help fighting a disease.
Another focus of gene therapy studies, besides ‘cargos’, is the vectors to
deliver those cargos into targeted tissue. Indeed, vector design and safety issues,
such as insertional mutagenesis and host immune responses to gene delivery systems
have become the major focus of the area of gene therapy (Romano, 2007). There are
several established gene-delivery systems among which the virus-mediated systems
are the most effective and widely studied.
Adenoviral vectors, second only to retroviruses, are among the most
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commonly used viral vectors because of their certain advantages over other vectors,
such as high transduction efficiency, ability to transduce a broad range of target cells,
capacity to package large sequences up to ~7.5kb, high levels of short-term
expression, and stability of recombinant vectors.
to both dividing and non-dividing cells.

Moreover, they can deliver genes

The most extensively used recombinant

adenoviruses (Ads) are generated from human Ads of serotypes 2 and 5.
Adenoviruses are non-enveloped icosahedrons with the outer structure
comprised of 240 hexons and 12 pentons at vertices of the icosahedral particle.

A

trimeric glycoprotein fiber projects from each penton terminating with a granular head.
A molecule on the host cell surface named coxsackie and adenovirus receptor (CAR)
can bind to the distal granular head of the fiber, and thus can initiate the receptor
mediated endocytosis of adenovirus.

During the process of endocytosis, besides the

interaction of fiber-CAR, adenoviral penton base also interacts with the alpha-v
subunit of a heterodimerized cell-surface receptor (composed of alpha-v and integrin
beta-1 subunits) by RGD motif to assist the endocytosis. After entering into the cell
cytoplasm, virus core escapes from the endosome and migrates towards the nucleus
where the double-stranded viral DNA is released from the degraded capsid and enters
into the nucleus through the nuclear pore. Interestingly, unlike many other viruses,
the viral DNA replicates and is transcribed in the host cell nucleus, but is actively
prevented from integrating into the host genome, which makes adenoviral vector an
ideal choice for preventing ‘insertional mutation’.

39

The adenoviral genome (Figure 1-4) is a linear double-stranded DNA about
30 to 38 kb consisting of two overlapping regions termed Early (E) genes and Late (L)
genes.

The genome is flanked by an inverted terminal repeats on each end.

E1

gene is required for the activation of transcription of all the early genes, therefore the
viral proteins can be significantly inhibited by disrupting E1 gene.
E1-deleted Ad vector is being used as vaccine carrier.

Currently, the

Deletion of both E1 and E3

genes can free up to 7.5kb for cloning gene of interest. E1- and E3-deleted Ad
vector is now available in many commercial kits and is widely used in gene therapy.
Although significant progress has been made in adenovirus mediated gene therapy for
cancer, great effort still needs to be taken to further reduce vector toxicity and
increasing gene transfer efficacy.

Figure 1-4. Genome of adenovirus and adenoviral vector. Adenoviral genes
are shown in green. Gene deleted in adenoviral vector are shown in dotted lines.
Gene and promoter introduced into adenoviral vector are shown in red.

A major problem caused by Adenovirus-mediated gene therapy is the
immunogenicity of adenovirus.

Methods such as chemical or genetic modifications
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on the recombinant adenoviruses have been explored to reduce this immunogenicity.
Chemical modifications have been made on fibers, penton bases, and hexon capsids of
adenovirus by covalently attached polymers to effectively reduce its toxicity and
immunogenicity.

Among those methods, modification of the fiber knobs with

PEGylated RGD is the most widely used.
Great progress has been made in Ads-mediated gene therapy by developing
helper-dependent adenoviral vectors (HDVs) in which all viral coding genes are
deleted.

In both small and large animal models, HDVs can significantly reduce the

chronic toxicity related to the early generation of adenoviral vectors after systemic
administration (Seiler et al., 2007).
Targeted delivery presents another major challenge.

The diffusion of

adenoviral vectors has been suggested as the major safety issue in Ad-mediated gene
therapy through local administration.

Adenoviral vectors administrated into the

desired site in the body often diffuse away to other tissues and organ systems.

Again,

modification on adenovirus is a promising way to develop targeted adenovirus vectors.
Scientists are seeking better ways to modify vectors without affecting their infectivity.
A new strategy for targeted adenovirus-gene delivery system, which takes advantage
of the extremely tight interaction between avidin/streptavidin and its ligand biotin,
was created in 2002 by Mark W. Pandori et al. (Pandori et al., 2002).

They

covalently conjugated biotin moieties to adenoviral vectors and coated silica
microbeads with streptavidin.

Biotinylated viral particles were stably and tightly
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immobilized on the solid surface, which virtually avoided the diffusion of adenovirus
into the solution.

In addition, they observed a marked increase in transduction

efficiency for target cells.
Since adenoviruses do not tend to integrate into the host genome, recombinant
adenoviral vectors have been very popular in cancer immunotherapy. A recent study
on IFN-γ gene transfer using adenovirus found a distinct difference in gene expression
profiles after IFN-γ treatment on skin lesions from 19 patients with cutaneous
lymphoma (CL).

Among the 495 differentially expressed genes, 251 genes

expressions were up regulated with a gene signature of induced type I and type II
IFNs, and the other 244 genes expressions were down regulated.

Their study also

provided evidence in support of the positive role of vector induced innate response in
tumor regression (Urosevic et al., 2007).
In addition, adenoviral vectors are also an effective way to deliver small
interfering RNA to the target cells.

The adenovirus-based siRNA gene transfer is

also a potential strategy for effective cancer treatment.

It has been demonstrated that

siRNA technology combined with Ad-mediated gene transfer is a promising approach
to silence gene expression in tumor cells for gene therapy or gene function studies.
Adenovirus-delivered HIF-1α-targeted siRNA can remarkably reduce the expression
of HIF-1α which leads to the enhanced hypoxia-mediated tumor cell apoptosis. In
addition, intratumoral injection of adenovirus-delivered HIF-1α-targeted siRNA had
significant negative effects on tumor growth (Zhang et al., 2004).
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5. Macrophage and cancer therapy
The dual role and plasticity of macrophages in the tumor tissue made it a
promising target for cancer gene therapy and immunotherapy where various ways are
sought to overcome immune silencing effects of the tumor microenvironment, thus
restore the antitumor activity of macrophages as well as the whole immune system.
As early as in 1974, Fidler by the first time applied ex vivo-activated
macrophages infusion to suppress pulmonary metastases in mice with B16 melanoma
(Fidler, 1974).

In human cancer treatment, monocytes have been isolated from the

cancer patients’ blood, and then matured by M-CSF and activated with LPS or IFN-γ
ex vivo.

After that, the activated macrophages were infused back into the patients,

but there was no clinical positive response to support that those macrophages have
antitumor activity (Andreesen et al., 1998).

Alternatively, it is reported that

macrophages ex vivo transfected by recombinant adenovirus with antitumor genes
such as IFN-γ and M-CSF had increased antigen-presenting activity and cytotoxicity,
resulting in increased antitumor potential (Lei et al., 2000).

Moreover, the

administration of autologous-derived macrophage activated killer (MAK) cells has
gained much progress in cancer immunotherapy (Ritchie et al., 2007). The tolerance
and activity of human autologous IFN-γ-activated macrophages have been assessed in
some pilot clinical trials in cancer patients.
On the other hand, in combination with the possible antitumor activities of
IRFs, the constitutively active forms of IRF-3 and IRF-7 have been delivered by
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adenoviral vectors into primary human macrophages to test their potential roles in
activating macrophages (Romieu-Mourez et al., 2006).

It was reported that

Ad-IRF-7-transduced macrophage exerted cytotoxic activities on cancer cells, and the
active form of IRF-7 could lead to novel antitumor effector functions.
In the present study, a novel macrophage-targeted, particulate-mediated gene
delivery system (Figure 1-5) was designed aiming to modulate the activation status of
the targeted macrophage cells for cancer therapy.

This system is to use zymosan

particles conjugated with recombinant adenoviruses encoding different interferon
regulatory factor (IRF) family genes, specifically IRF1, IRF3, and IRF7.

We

hypothesized that the intracellular expression of IRF gene in macrophage cell line
could lead to the activation of NF-κB, which in turn induces some important
inflammatory cytokines downstream of NF-κB signal transduction pathway, resulting
in the macrophages’ antitumor activities.
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Figure 1-5. Scheme of macrophage-targeted, particulate-mediated adenoviral
gene delivery system.

Top-left: recombinant adenovirus carrying an IRF gene.

Top-right: biotinylated adenovirus.

Bottom-left: streptavidin-coated zymosan.

Bottom-right: streptavidin-coated zymosan conjugated with biotinylated adenovirus.
Note: molecules and viruses are not drawn to scale.

The tumors can polarize macrophage into non-immune response state which
usually shut down the NF-κB pathway.

NF-κB is the key mediator in a variety of

pathways initiated by bacterial products, viruses, as well as tumor cells. In the
NF-κB network, IRFs also play important roles, and it can also regulate IFNs
expression. And the expression of IFNs is also a feature of antitumoral macrophages.
Taking together, as we hypothesized, intercellular increasing of IRF family genes
could be an effective way to turn on the NF-κB-mediated pathways which could result
in the activation of immune responsible macrophages.
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Additionally, this novel strategy used zymosan to modify the adenoviral
vectors through a very strong non-covalent biological interaction between biotin and
streptavidin.

The adenovirus-zymosan particles delivery system has several

advantages over adenovirus-only or adenovirus-conjugated microbeads system.
Firstly, adenoviral techniques are designed to achieve high efficiency gene delivery,
and zymosan can be targeted by macrophages. The adenovirus-conjugated zymosan
particles can be large enough targeted by macrophages only.

We designed these

novel vectors to achieve effectively targeted delivery of interested genes. Secondly,
magnetic beads can result in the cell death, usually after two days incubation, while
zymosan is bio-degradable in macrophages.
In the following chapter, detailed procedures and techniques of this study will
be included, from construction of recombinant adenoviral vectors to packaging
recombinant viruses, and from infection of macrophage cell line to the assay tests.
There are two main objectives in this study: to test (1) if or not the new designed
technique is good for targeted delivery of genes into macrophages; (2) if or not the
intracellular delivery of IRFs can result in the production of desired cytokines or other
effector molecules.
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CHAPTER TWO
MATERIALS AND METHODS

1. Construction of adenoviral vectors
1.1. Acquisition of wildtype IRF and EGFP genes
Coding sequences (CDSs) for wildtype interferon regulatory factors (IRFs)
were obtained from Invivogen (San Diego, CA) in expression vectors pUNO-mIRF1,
pUNO-mIRF3 and pUNO-mIRF7, which were shipped as transformed and
lyophilized E.coli (strain GT116).

The lyophilized E.coli was resuspended and

grown on Fast-Media Blas (LB agar supplemented with blasticidin) following the
manufacture’s protocol. Ten colonies of E.coli containing each gene were isolated
and seeded in 3ml of Fast-Media Blas liquid medium and shaken at 37°C for
overnight. Plasmid was prepared from each culture using QIAprep-mini kit.
As a control gene, enhanced green fluorescent protein (EGFP) was used to
substitute mIRF1 gene fragment in the pUNO-mIRF1 vector.

The EGFP gene was

first amplified by PCR from pIRES2-EGFP (Clontech) to introduce EcoRV restriction
sites on both ends, and then ligated into pCR2.1-topo vector to generate
pCR2.1-EGFP.

The EcoRV fragment of pCR2.1-EGFP containing EGFP CDS was

ligated to pUNO backbone which was generated from pUNO-mIRF1 vector by
AgeI/NheI (New England Biolab, NEB)-digestion to remove mIRF1 CDS,
gel-purification and blunting using Klenow fragment (NEB), resulting in
pUNO-EGFP.
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1.2. Construction of entry vectors
The expression cassettes on pUNO plasmids containing EF-1α promoter,
HTLV 5’ untranslated region (UTR), CDS of IRFs or EGFP and SV40
polyadenylation signal were transferred to pENTR4 vector (Invitrogen) by restriction
enzyme-digestion and ligation to create Entry clones.
The restriction enzymes used for subcloning of each gene are listed in Table
2-1.
Gene

Enzymes to cut inserts
on pUNO vector

Enzymes to cut
pENTR4 vector

Blunted?

pUNO-mIRF1

NotI and SwaI

EcoRI

Yes

pUNO-mIRF3

SwaI and XhoI

EcoRV and SalI

No

pUNO-mIRF7

SwaI and XhoI

EcoRV and SalI

No

pUNO-EGFP

SwaI and XhoI

EcoRV and SalI

No

Table 2-1. Restriction enzymes used in cloning IRF and EGFP genes into Entry
vectors.

As indicated above, if the ends generated by the enzymes are not

compatible with the ends of the digested Entry vector, the insert and the vector was
blunted by Klenow fragment (NEB) or by Quick Blunting Kit (NEB).

The digested

and blunted pENTR4 vector was dephosphorylated by Antarctic phosphatase (NEB)
before ligation. Ligation products were transformed to Top10 chemically competent
cells which were plated on LB agar plates supplemented with Kanamycin for
overnight growth at 37oC. Colonies were picked for each gene and were inoculated
into media culture. Plasmids were extracted using Miniprep kit (Qiagen) and cut
with appropriate enzymes to check the correct clones.

The correct plasmids (entry

clones) were then proceeded to the LR recombination reaction with pAD/PL-DEST
vector.

1.3. Mutagenesis to generate superactive IRF3 and IRF7
Mutagenesis was performed using FINNZYMES Phusion site-directed
mutagenesis kit (product code F-541).
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The primers were designed according to the type of desired mutations
following the kit instruction.

The point mutation of mIRF3 gene was generated by

designing a mismatch in the mutagenic primer.

According to the kit instruction, the

desired mutation was in the middle of the primer flanked by 10-15 perfectly matched
nucleotides on each side.

The deletion of mIRF7 was created by designing primers

that border the deleted region on both sides and perfectly match the template.

In

both cases the primers were phosphorylated at 5’ end for subsequent ligation. Tms
were calculated using the nearest-neighbor-method-based calculator on Finnzymes’
website (www.finnzymes.com).
For ‘super activated’ mIRF3-Mut3 which contains S396D mutation,
PrimerMut31 (5’p-ctcccttaccgatgaccagtacaag, bolded letters denotes the introduced
point mutation) and PrimerMut32 (5’p-ataggctggctgttggagatg) were used to amplify
the whole plasmid following the manufacture’s instruction.
Similarly, PrimerMut71 (5’p-gtatgcaaggcatacctggagg) and PrimerMut72
(5’p-ctcggtgagagctggctgtt) were used to amplify the whole plasmid to generate
truncated IRF7 (lacking residues 238~410).
3μl (about 25ng) of PCR product from mutagenesis reaction was used to
proceed with ligation step in a 10μl ligation reaction using 0.5ul of Quick T4 DNA
ligase (NEB).

Ligation products were then transformed into one-shot Top10 cells.

Mutated plasmids were verified by sequencing.
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1.4. Construction of adenoviral vectors
The expression cassettes in pENTR4 vector flanked by recombination sites
attL1 and attL2 were shuttled to adenoviral vector pAd/PL-DEST (Invitrogen) by LR
recombination according to the product manual.
After the recombination reaction, 5μl of reaction mix was transformed into
one vial of the TOP10 competent cells.

The transformed cells were plated on the LB

agar medium supplemented with Ampicillin and incubated in 37°C incubator
overnight.
Four colonies of each plate were picked, dotted gently onto the
chloramphenicol LB plates and transferred into Ampicillin LB liquid medium.

The

plates and liquid culture were incubated in 37°C incubator overnight. The correct
plasmids should not grow on the chloramphenicol LB plates due to the lost of CAMR
gene between attR1 and attR2 sites during LR recombination.

The resultant

plasmids were extracted using Miniprep kit (Qiagen).
2. Production and purification of adenoviral particles
Adenoviral particles were produced in packaging cell line AD293 (Clontech)
by transfection of linearized adenoviral plasmid DNA.

AD293 cell line, a derivative

of the commonly used HEK293 cell line (human embryonic kidney cells transformed
by sheared adenovirus type 5 DNA), has improved cell adherence and plaque
formation properties.

AD293 cells produce the adenovirus E1 gene in-trans,

allowing the production of infectious viral particles when the cells are transfected
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with E1-deleted adenovirus.
2.1. Transfection and preparation of initial viral stock
AD293 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen, CA) supplemented with 10% fetal bovine serum (BSA), 100
units/ml penicillin and 100 μg/ml streptomycin, at 37°C and 5% CO2.
Before transfection into AD293 cells, the adenoviral vectors were digested by
PacI to expose the left and right viral inverted terminal repeats (ITRs) which allows
proper viral replication and packaging.
Transfection was performed using LipofectamineTM 2000 following the
protocol provided by Invitrogen.

Briefly, the day before transfection, AD293 cells of

>90% confluency in one T75 flask were trypsinized, counted and plated into 6-well
plate with 5×105 cells/well in 2ml medium.

On the day of transfection, the culture

media were replaced with 1.5ml of OpitMEM I Medium containing serum but no
antibiotics.
For each construct, ~2μg linearized adenoviral vector DNA was used for each
transfection.

The linearized adenoviral vector DNA was diluted in 250μl of

Opti-MEM I medium without serum and mixed gently.

Then 6μl of Lipofectamine

2000 was diluted in 250μl of Opti-MEM Medium without serum, mixed gently, and
incubated for 5 minutes at room temperature (RT).

After 5 minutes incubation, the

diluted DNA and the diluted LipofectamineTM 2000 were combined together and
mixed gently.

The mixture was then incubated at room temperature for 20 minutes,
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allowing

the

DNA-Lipofectamine

2000

complexes

to

form.

Each

DNA-LipofectamineTM 2000 complex was added dropwise to each well in 6-well
plate and mixed well by shaking the plate back and forth.

The transfected cells were

incubated overnight at 37°C in a 5% CO2 incubator.
The medium containing the complex was removed and replaced with complete
culture medium the next day after transfection.

On the third day (48 hours post

transfection), the cells were trypsinized and transferred to a sterile 10cm tissue culture
plate containing 10ml of complete culture medium.

The culture media were changed

every 2-3 days if needed until visible regions of cytopathic effect (CPE) were
observed.

Then the culture media were maintained or replenished to allow the

infections to proceed until 80% CPE were observed. The adenovirus-containing
cells were harvested and transferred into sterile capped tubes.

The harvested cells

were be stored in -80°C or made into crude viral lysate directly.
For preparing a crude viral lysate, the harvest cells together with the medium
were centrifuged at 300g for 5 minutes.

The supernatant (usually 5ml of supernatant

was left for resuspending the cell pellets) was transferred to a new sterile capped tube
and stored in -80°C.

The cell pellets were resuspended in the remaining medium.

The resuspended cells were freezed on dry-ice-acetone bath and then thawed
in 37°C water bath.

The freeze-thaw cycle was repeated for 4-5 times.

After the

last thaw step, the lysed cell cultures were centrifuged at 3,000rpm for 15 minutes.
The supernatant was collected in a new capped tube and labeled as cell lysate.
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2.2. Verification of transgene by Western Blot
The productions of IRF proteins in AD293 cells were examined by Western
Blotting. The protocol is described briefly as follows.
2.2.1. Preparing cell lysates from 6-well plates
The cell culture media were removed and the cells were washed once with
ice-cold PBS.

After aspirating PBS, 200µl 1×ice-cold lysis buffer supplemented

with appropriate amount of protease inhibitor was added to each well. The plate was
incubated on a shaker for 10min.

The lysed cells in each well were transferred to a

1.5ml microcentrifuge tube and gently pipetted up and down by using a 1cc syringe
and 23-gauge needle to shear the genomic DNA.

Then the tubes were incubated on

ice for 20min and centrifuged at 14,000rpm for 10min at 4oC. The supernatants (cell
lysates) were transferred to new tubes and stored at -20oC for future use. The protein
concentrations were measured by the Bradford Assay.
2.2.2. PAGE and Western blotting
According to the protein concentration, up to 30µl lysate (ddH2O was used to
dilute samples when necessary) was added into a 1.5ml tube.

The same amount of

positive control was used and 30µl of 2× lamini buffer was added to each sample and
control tube.

15µl of prestained protein marker (NEB) was used each time.

The

samples, controls, and marker were denatured in boiling water for 5min and then
chilled on ice.
50μl of each sample or control was loaded in each lane of 4-15% SDS-PAGE
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gel.

The running condition was set at 100V (constant voltage) for 1hr 30min.

running buffer was 1×TGS.

The

The proteins were transferred to nitrocellulose

membrane after running in 1×transferring buffer at 100V for 50min.
After membrane-transfer, the membrane was blocked in 15ml 5% milk/TBST
on shaker for one hour at room temperature. The membrane was washed 3 times
(5min each) with TBST. Then the membrane was incubated in primary antibody
diluted with 10ml 5% BSA/TBST (dilution range was 1:500~1:1000) on the shaker at
4oC overnight.

The next day, the membrane was washed 3 times (5min each) with

TBST and incubated in horse radish peroxidase (HRP)-conjugated secondary antibody
(diluted with 10ml 5% milk/TBST) on the shaker at room temperature for 4~6hr, after
which the membrane was washed 5 times (5min each) with TBST.
The membrane was then transferred into a clean dish and soaked in 10ml
enhanced chemiluminescent Western blotting detection reagents for 1min and
immediately used for film exposure and development.

The exposure time was

usually 30s~10min.
2.3. Viral particle amplification
Amplification of adenoviral particles was done by infecting AD293 cells with
initial viral stock. The day before infection, the cells (>90% confluent in T75 flask)
were trypsinized, counted and plated at the density of 3×106 cells per 10cm plate in
10ml complete growth medium.

On the day of infection, the cells were verified at

80~90% confluency, and then were infected by 1ml of crude viral lysate.
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The

infected cells were incubated at 37°C in a CO2 incubator until 80~90% of the cells
rounded up or loosely attached to the tissue plates (4-5days post infection).
The cells were harvested and made into lysate by using the same procedure as
described above.

To make the desired amount of adenoviruses, the following

amplification procedures were performed.
Second round amplification:

The adenovirus of each type was amplified by

using the lysate from 10cm dish culture to infect one T75 flask of AD293 cells.
Third round amplification:

The adenovirus of each type was amplified by

using the lysate from T75 flask to infect eight T150 flasks of AD293 cells.
2.4. Viral particle purification
ViraBind Adenovirus Purification Kit (Cell Biolabs) was used to purify viral
particles. Before purification, the lysate from eight T150 flasks of infected AD293
cells was thawed in 37°C water bath and passed through a 0.45μm sterile filter to
remove cell debris.

Then the viral lysate was purified by following the purification

protocol as shown in Figure 2-1.

Briefly, the viral lysate was passed through

0.45μm filter first before purification.
wash buffer.

The purification filter was pre-rinsed with

Due to the limitation of the capacity of the filter, half of the lysate was

passed through purification filter first followed by the steps as shown in the
flow-chart. After filter regeneration, the other half of the lysate was purified by
following the same procedure.
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5ml 1xWash
Buffer prerinse
Viral lysate

0.45μm filter

Half of the lysate

Purification
filter

Second time

Purification
filter
10ml 1xWash Buffer, 3
times

Purification
filter
3ml elution buffer

Regenerated
filter

5ml 1xWash Buffer

10ml Regeneration Buffer

Purification
filter

Flow-through
(purified viral
particles)

Figure 2-1. Flow-chart of viral particle purification.

2.5. Viral particle concentration
The eluate (containing purified virual particles in elution buffer) from the last
step was then concentrated by using 100,000MWCO Vivaspin 20 centrifugal
concentrator (Vivoscience).

The eluate was applied into Millipore tube and

centrifuged at 3500×g for 15~20min until the desired volume was achieved.
2.6. Buffer exchange
After concentration, the buffer used to suspend viral particles was changed to
PBS.

The buffer exchange step was done by using 5ml ZedaTM Desalt Spin

Columns (Pierce) according to the manufacturer’s protocol. Briefly, a new column,
with the bottom closure twisted off and cap loosened, was placed into a 15ml conical
collection tube.

Then the column was centrifuged at 1,000×g for 2min to remove
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storage solution.

Then 2.5ml of buffer for exchange (PBS) was added to the column

and the column was centrifuged at 1,000×g for a minute to remove buffer.

This step

was repeated for three times after which the column was placed into a new collection
tube.

The sample (concentrated eluate) was loaded to the center of the compact resin

bed. To ensure maximal protein recovery, a stacker (100μl) of PBS was applied to
the resin bed after the sample was fully absorbed.
After buffer exchange, the virus/PBS solution was passed through a 0.2μm
filter and stored in -80°C for future use.
2.7. Determination of viral titers.
The viral infectivity of the purified, concentrated, and buffer-exchanged
recombinant viral samples were measured by using QuickTiterTM Adenovirus Titer
Immunoassay Kit (Cell Biolabs, CA).
AD293 cells were harvested and resuspended in culture medium at the
density of 2.5×105 cells/ml.
24-well plate.

1ml of the cell culture was seeded in each well of a

The plate was incubated at 37°C, 5% CO2 for 1 hour.

During the 1hr incubation, the serial dilutions of the five samples were
prepared by a series of 1:100 and 1:10 dilution as shown in Figure 2-2.
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2μl original
viral sample

198μl
medium

180μl
medium

180μl
medium

20μl

10-2

180μl
medium

20μl

10-3

10-4

10-7

Figure 2-2. Scheme of serial dilution of viral stock.

After one hour incubation, the cells were infected by 100μl of the diluted
samples and one well of cells were “infected” by 100μl of medium as a negative
control. The plate was incubated at 37°C, 5% CO2 for 2 days.
After two days incubation, the immunostaining step was performed by
following the kit protocol as shown in Figure 2-3.
Remove
medium

Add 0.5ml/well cold
methanol

Aspirate DAB, wash with
PBS, 2 times

Incubate 20mins,

Wash with PBS

-20°
C

3 times×5mins/each

Add 1ml/well PBS,
count brown cells,
calculate viral titer

Aspirate BSA, add 0.25ml/ml 1st
antibody, incubate 1hr, RT

Add 0.25ml/well 1×DAB,
incubate 10mins, RT

Wash with PBS
5 times×5mins/each

Add 1% BSA/PBS,
incubate 1hr, RT

Add 0.25ml/well 2nd antibody,
incubate 1hr, RT

Figure 2-3. Flow-chart of titer determination.
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Wash with PBS
3 times×5mins/each

3. Biotinylation and conjugation of viral particles
3.1. Biotinylation
The biotinylation reagent used in this study was NHS-LC-LC-Biotin in
water-free DMSO at a concentration of 50mg/ml (Pierce).

5μl of Biotinylation

reagent (diluted in DMSO to 3mg/ml) was added into 200μl adenoviral stock (~107
viral-particles/200μl) and mixed well.

The mixture was incubated on ice for 2 hours.

The residual biotinylation reagent was removed by spin chromatography at
14,000rpm on a 2ml Zeda Desalt Spin Column (Pierce).

This step was repeated 3~4

times by adding proper amount of PBS and spinning down. Finally, 100~200μl of
PBS was added to the column to resuspend the biotinylated viral particles in a total
volume of 300μl.
3.2. Conjugation with zymosan
The yeast fraction Zymosan A (purchased from Sigma, product number:
Z4250) was conjugated to streptavidin using protocol previously developed by the Yu
Lab (see Appendix B).
Streptavidin-Zymosan pellets are kept in Hepes-buffered saline (HBS) after
preparation.

Before use, the buffer was changed to PBS by centrifugation.

3μl of

Streptavidin-Zymosan/PBS was added to each of the biotinylated adenovirus solution
and mixed well. The mixture was incubated on an orbital shaker at room temperature
for 1hr, after which the mixture was centrifuged at 14,000rpm for 2min.

The

supernatant was discarded and the adenovirus-zymosan particles were resuspended in
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200μl PBS.
4. Infections and functional assays of macrophages
RAW-Blue cell line (purchased from Invivogen, San Diego, CA) is a mouse
macrophage reporter cell line derived from RAW264.7 macrophage.

RAW-Blue

cells are stably transfected with an expression cassette that produces the secreted
embryonic alkaline phosphatase gene (SEAP) under the control of transcription
factors NF-κB and AP-1.

In this study, the activity of NF-κB and AP-1 can be

measured by a colorimetric alkaline phosphatase assay QUANTI-Blue.
4.1. Infection of RAW-blue reporter cells
The day before infection, the RAW-Blue cells were seeded in 6-well plate at
the density of 5×105cells per well in 2ml complete medium (DMEM supplemented
with 10% BSA, 100 units/ml penicillin and 100 μg/ml streptomycin) supplemented
with 200μl/ml Zeocin.

On the day of infection, the medium was changed to DMEM

without phenol red (D1145, Sigma). Then, 100μl of each adenovirus-zymosan/PBS
sample was added dropwise to one well.

Each sample was done in duplicates.

cells were incubated at 37°C in a CO2 incubator for two days.

The

The supernatants

were collected and the cells were prepared into lysate.
4.2. QUANTI-Blue assay
The QUANTI-Blue kit (purchased from Invivogen, San Diego, CA) is a
colorimetric enzyme assay specifically to determine the activity of SEAP in the
supernatants of cell cultures.

In the presence of SEAP, the QUANTI-Blue medium
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turns purple-blue, which in turn indicates the activity of NF-κB and AP1. The assay
was done by following the kit protocol.
One bag of Quanti-blue mix was dissolved in 100ml ddH2O and passed
through a 0.22μm filter. 200μl of Quanti-blue reagent was added to each well in a
96-well plate, and then 5μl cell supernatant of each sample was added to the reagent.
The plate was incubated at 37oC for 1~24hr. The SEAP activity was assessed by
reading the OD at 655nm with a microplate reader (Bio-rad).
4.3. Nitric oxide quantification
The total nitrate/nitrite concentrations of the cell supernatants were determined
by using the Nitric Oxide Quantitation Kit (Active Motif, CA).

The nitrate assay

and/or nitrite assay were done by following the kit protocol.
Nitrate assay: The standard, blank, and sample wells were prepared by
adding the reagents or samples as shown in Table 2-2.
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Well

Nitrate Standard
200μM NaNO3 (μl)

Samples (μl)

1×Assay Buffer (μl)

A1

0

-

70

B1

5

-

65

C1

10

-

60

D1

15

-

55

E1

20

-

50

F1

25

-

45

G1

30

-

40

H1

35

-

35

Blanks

-

-

70

Samples

-

70

-

Table 2-2.

Sample preparation in nitrate assay.

20μl reconstituted cofactors solution (one vial of lyophilized cofactor was
dissolved in 1.2ml ice-cold ddH2O) was added to each well.

10μl reconstituted

nitrate reductase solution (one vial of lyophilized nitrate reductase was dissolved in
0.6ml ice-cold 1×assay buffer) was added to each well.

The plate was placed on a

rocking platform to mix the solutions at 150rpm for one minute then incubated at RT
in the dark for 30min.
After the incubation, 50μl Griess reagent A was added to each well followed
by immediately adding 50μl Griess reagent B to each well. The plate was incubated
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for another 20min at room temperature to allow the color to develop.

The

absorbance was read on a spectrophotometer at 540nm with a reference wavelength of
655nm.
Nitrite assay:

The standard, blank, and sample wells were prepared by

adding reagents or samples as in Table 2-3.
Nitrate Standard
200μM NaNO2 (μl)

Well

Samples (μl)

1×Assay Buffer (μl)

A1

0

-

100

B1

5

-

95

C1

10

-

90

D1

15

-

85

E1

20

-

80

F1

25

-

75

G1

30

-

70

H1

35

-
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Blanks

-

-

100

Samples

-

100

-

Table 2-3.

Sample preparation for nitrite assay.

50μl Griess reagent A was added to each well, and 50μl Griess reagent B was
added immediately afterwards.
temperature.

The color was developed for 10min at room

The absorbance was read on a spectrophotometer at 540nm with a

reference wavelength of 655nm.
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The standard curves were generated by plotting the absorbance values versus
nitrate or nitrite concentrations.

The total NO production of a sample was calculated

by nitrate standard curve, and the endogenous nitrite concentration was calculated by
nitrite standard curve.
4.4. Western blotting:
Phosphorylated p65 protein in RAW-Blue cells was analyzed by Western
Blotting. The protocol was similar to the one described in Section 2.2, except that
phosphatase inhibitor was added in cell lysate.
4.5. Cytokine array:
The cytokine productions in the culture supernatants were analyzed by using
Proteosome Profiler TM Array-Mouse cytokine array panel A array kit (purchased
from R&D System).
Briefly, 2.0ml of Array Buffer 6 was pipetted into each well of the 4-well
multi-dish.

The membranes were placed into each well with the identification

numbers facing upward.

For the blocking step, the dish was incubated at room

temperature on a rocking platform for one hour. During the blocking, samples were
prepared by adding 800μl of culture supernatants, 200μl of Array Buffer 5, and 0.5ml
of Array Buffer 4 in separate tubes. Then 15μl of detection antibody cocktail was
added to each tube.

The samples were mixed and incubated at room temperature for

one hour. Array Buffer 6 was aspirated from the wells after one hour incubation and
the samples were added into each well. The dish was incubated overnight at 2~8°C
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on a rocking platform.
The membranes were removed into 4 individual plastic containers with 20ml
of 1×Wash Buffer. The dish was rinsed with ddH2O and dried thoroughly.

The

membranes were washed for three times, 10min each wash, on a rocking platform.
The streptavidin-HRP solution was diluted in Array Buffer 5 and 1.5ml of the diluted
streptavidin-HRP was added into each well of the dish.

The membranes were

returned to the dish containing streptavidin-HRP and incubated at room temperature
for 30min on a rocking platform.

After the incubation, the membranes were washed

as described above followed by the incubation with ECL.

The membranes were

placed on the same plastic sheet protector and covered with plastic wrap, and then
exposed to X-ray film for 1-10min.
The positive signals on the film were identified by laying the transparency
template from the kit over the image.

The three pairs of positive control spots were

provided as position-setting spots. The data were quantified by scanning the film on
a transmission-mode scanner and analyzing the array image using software ImageJ.
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CHAPTER THREE
RESULTS

1. Construction of recombinant adenoviral vectors
The strategy used to construct adenoviral vectors expressing mIRF1, mIRF3
and mIRF7 are outlined in Figure 3-1. The expression cassettes containing the
hEF1-HLTV hybrid promoter, the coding sequence of a desired IRF gene, and the
SV40 polyadenylation signal were excised from pUNO vectors and ligated into
pENTR4 backbone through sticky-end or blunt-end ligations (Table 2-1), resulting in
Entry clones.

Entry clones were then recombined with promoterless adenoviral

destination vector pAD/PL-DEST through LR-recombination to generate destination
clones.
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Figure 3-1. Construction of adenoviral vector (using mIRF1 as an example).
Bacterial expression elements are shown in yellow; bacterial replication origins are
shown in pink; recombination sites are shown in purple; mammalian promoters are
shown in green; mammalian polyadenylation sequences are shown in light blue;
selection markers are shown in orange; adenoviral elements are shown in navy blue.
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The lengths and directions of inserts in entry clones were checked by
restriction-enzyme digestions (Figure 3-2A).

As shown in Figure 3-2B and Figure

3-2C, multiple clones for each gene showed correct restriction fragment patterns.
One of these correct clones for each gene was picked for LR recombination.
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Figure 3-2.

Restriction-enzyme digestions of pENTR4-mIRF1, -mIRF3 and

–mIRF7. (A) Selection of restriction enzymes for pENTR4-IRF1. (B) and (C)
Restriction-enzyme digestion of mIRF1 (B), mIRF3 and mIRF7 (C).
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To construct control adenoviral vector expressing EGFP, coding sequence for
EGFP was first PCR-amplified from pIRES2-EGFP vector and then cloned into
pCR2.1-TOPO vector. EcoRV digestion of the resulted clones showed that one of
these clones has the correct insert (Figure 3-3A).

The EcoRV fragment was then

used to substitute mIRF1 CDS in pUNO-mIRF1 to generate pUNO-EGFP. The
expression cassette of pUNO-EGFP was again cloned into pENTR4 and transferred
into pAD/PL-DEST through LR-recombination.

The correctness of pUNO-EGFP

and pENTR4-EGFP was also checked by diagnostic restriction-enzyme digestion
(Figure 3-3B, Figure 3-3C).
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Figure 3-3. Restriction-enzyme digestions of pCR2.1-EGFP (A), pUNO-EGFP
(B) and pENTR4-EGFP (C). Correct clones are indicated by arrows on the top of
the images.

2. Mutagenesis
The super-active IRF3 (Mut3) was generated by substitution of Ser396 with
Asp, with corresponding DNA sequence changed from TCT to GAT.

The

super-active IRF7 (Mut7) was generated by deletion of amino acid residues 238-410.
Mutagenesis was performed at the level of Entry vector using whole-plasmid PCR
strategy.

Sequencing of resultant plasmids (Figure 3-4) showed that desired

mutation and deletion was correctly introduced.
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Figure 3-4.

Construction strategies and sequencing results of super-active

mutants of mIRF3 (A) and mIRF7 (B).

3. Verification of transgene expressions by Western blotting
The expression vectors pAD/PL-DEST containing mIRF or EGFP genes was
linearized by PacI-digestion to expose viral ITRs flanking the vector dsDNA on both
sides.

The linear dsDNA were transfected into AD293 cells to initiate viral

replication and transgene expression.

The expressions of transgenes in AD293 cell

crude lysate and supernatant were examined by Western Blotting (Figure 3-5).

All

mIRF1, mIRF3, mIRFmut3, mIRF7 and mIRFmut7 can be readily detected.
Unexpectedly, although the transgenic proteins should only be produced in the cells
and not secreted in the supernatant, the mIRF1 protein can also be detected in
supernatant, which might be due to cell death or other reasons.
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Figure 3-5.

Detection of transgene expression in AD293 cell by Western

blotting. (A) mIRF1. (B) mIRF3 and Mut3. (C) mIRF7 and Mut7.

Lanes for cell

lysate and supernatant are labeled on the top of the figures in light blue or red text.
Size markers are shown in red and the band for 47.5kD is labeled.
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4. Adenoviral titer
To assess the infectivity of the recombinant viral particles, the titer of
adenoviral stocks were measured after purification, concentration and buffer exchange.
The calculated titers were shown in Table 3-1. Due to some unidentified reasons,
the titer of Ad-Mut7 was still undetectable, and the titers for Ad-mIRF1 and Ad-Mut3
are much lower than the other three.

Titer
(IFU/ml)

Ad-EGFP

Ad-mIRF1

Ad-mIRF3

Ad-Mut3

Ad-mIRF7

1.2×1010

1.8×108

3.4×1011

1.3×108

2.5×1010

Table 3-1. Recombinant adenovirus titer.

5. Expression of transgenes in macrophage cell line transduced with
adenovirus-conjugated zymosan particles
The adenovirus-zymosan conjugates were made according to the procedures
described in Section 3 of Chapter 2.

RAW-Blue cells were infected in vitro with

adenovirus-zymosan conjugates at a MOI of ~10PFU/cell.

Two wells of a 6-well

plate were transduced with a same viral stock as duplicate. The same amount of
fresh medium was added to two wells as negative control. 24hr and 48hr after
infection, the macrophages transfected with zymosan-Ad-EGFP conjugates were
examined under fluorescent microscope to observe the expression of reporter gene
EGFP. As shown in Figure 3-6, after 48hr infection, nearly 100% transduction
efficiency was observed.
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Figure 3-6. RAW-Blue macrophage cells transfected with zymosan-Ad-EGFP
conjugates express EGFP gene. Fluorescent microscopic pictures were taken at
48hr after infection.

After verifying the expression of EGFP, the culture supernatants and cell
lysates were collected separately for the functional assays. In summery, totally 24
samples (lysate and supernatant) from the 12 experimental wells (2 replica for each
treatment or control), were collected.
6. Effects of NF-κB activation in adenovirus-zymosan conjugate-transduced
RAW-Blue cells
The activation of NF-κB was analyzed by a colorimetric reporter assay
(QUAITI-Blue assay) as indicated in Section 4.2 of Chapter 2. The RAW-Blue
cells are engineered to carry a stably-integrated expression cassette to produce
secreted

embryonic

alkaline

phosphatase

(SEAP)

under

the

control

NF-κB/AP-1-inducible promoter. Thus, the SEAP activity in culture supernatant
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reflects the intracellular activity of NF-κB.

The QUANTI-Blue medium changes to

a purple-blue color in the presence of SEAP.

To test whether NF-κB could be

activated in the macrophages by transfected genes, 5μl of transfected or untreated
macrophage culture supernatant was subjected to QUAITI-Blue assay where the
SEAP activity was measured (Figure 3-7).

Compared with blank wells and

untreated cell samples, color change caused by the SEAP activity was readily
observed in all the transfected cell culture supernatants (Figure 3-7A).
Quantitatively, the OD655nm values of cell treated by adenovirus-zymosan conjugate
were 3~8-fold higher than the blank and untreated ones, suggesting NF-κB activation
in transfected cells.
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Figure 3-7.

In vitro effects of adenovirus-conjugated zymosan particles on the

activation of NF-κB. (A) QUANTI-Blue assay for the detection and quantification
of SEAP in culture supernatant. In the presence of SEAP, the medium changes to a
purple-blue color. (B) Quantification (OD655nm) of (A). Blank: fresh medium
only; UT: untreated cells (i.e. supernatant of cells treated with medium). RAW-Blue
cells were seeded in 6-well dishes at 5×105 cells/2ml each well. The next day, they
were infected with the adenovirus-zymosan particles at the indicated MOI
(~10PFU/cell). The supernatants were collected from duplicate wells after 48hr. The
activation of NF-κB was assessed by measuring the level of SEAP by QUABTI-Blue
assay. Blank: fresh medium only; UT: untreated cells (i.e. supernatant of cells treated
with medium).
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7. Total nitric oxide production in culture supernatants of adenovirus-zymosan
conjugate-transduced RAW-Blue cells
Nitric oxide (NO) is a key effector molecule associated with the tumoricidal
activity of activated macrophages.

To determine the possible production of this

cytotoxic molecules in the transfected cells, the NO production in each sample was
measured.

Interestingly, the NO productions in the IRF-transfected samples were

even lower than EGFP-transfected cells, and all the transfected samples had even
lower NO productions than untreated ones.

As indicated in Figure 3-8, a significant

increase of the NO production in the treated cells was not observed. However, the
result is not conclusive, as a lot of studies showed that NO production is unstable and
also hard to reflect the real amount in the cell cultures (See Chapter 3).

Figure 3-8.

In vitro effects of adenovirus-conjugated zymosan particles on the

NO production.

RAW-Blue cells were seeded in 6-well dishes at 5×105 cells/2ml

each well. The next day, they were infected with the adenovirus-zymosan particles at
the indicated MOI (~10PFU/cell). The supernatants were collected from duplicate
wells after 48hr. The NO production was measured by NO quantification kit. Blank:
kit reagent only; UT: untreated cells (i.e. supernatant of cells treated with medium).
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8. In vitro effects of adenovirus-zymosan conjugates on cytokine production in
transduced macrophage cell line.
As an important mediator between innate and adaptive immunity, the activated
macrophages can produce a variety of effector molecules, among which cytokines
have critical roles in conferring the antitumor activity of macrophages.

The

cytokines secreted in the cell culture supernatant can also reflect the possible
activations of some related signaling pathways.

In order to determine whether the

treated macrophages can produce M1-like cytokines, a cytokine array was used to
detect the expressions of a series of cytokines (Figure 3-9).
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Figure 3-9.

In vitro effects of adenovirus-conjugated zymosan particles on the

cytokine productions. (A) Cytokine array images scanned from X-ray films. The
films were exposed for 10min. The cytokines were captured by spotted antibodies on
the membranes in duplicates. The cytokine types were indicated in the colored
squares.

Note: the red squares are for positioning; the blue ones indicate the

possible M1-like cytokines; the purple ones are possible M2-like cytokines; the
yellow ones indicate untypical cytokines for M1/M2. (B) Quantification of (A).
RAW-Blue cells were seeded in 6-well dishes at 5×105 cells/2ml each well. The next
day, they were infected with the adenovirus-zymosan particles at the indicated MOI
(~10PFU/cell). The supernatants were collected from duplicate wells after 48hr.
The cytokines secreted in the supernatants were detected by Mouse Cytokine Array
Panel A Array. Blank: fresh medium only; UT: untreated cells (i.e. supernatant of
cells treated with medium). Refer to the appendix for the cytokine abbreviations.
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As Figure 3-9A and Figure 3-9B indicated, increased production of certain
cytokines was observed in the treated cells. However, compared with Ad-EGFP
transfected cells, there were no significant increase of cytokine productions in the
Ad-IRF-transfected cells.

Some M1-like cytokines (indicated by blue squares in

Figure 3-9A and Figure 3-9B) possibly downstream of TLR/NF-κB pathway were
induced or up-regulated.

One of the M2-like cytokine, IL-1ra, was also observed in

the treated cells but not in untreated cells. The G-CSF and sICAM-1 are not found
to be typical markers of M1 or M2, but they could be involved in inflammation.
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CHAPTER FOUR
DISCUSSION

Macrophages are indispensable for competent immune defense against
pathogens as well as malignant cells.

Besides their ability to directly eliminate

invaders by phagocytosis, they can also secrete a wide variety of effector molecules
resulting in multiple functions, including tumoricidal activity.

The gene expression

patterns

influenced

and

functions

microenvironmental signals.

of

macrophages

are

greatly

Macrophages are highly plastic.

by

the

As demonstrated by

previous works, TAMs can be ‘re-educated’ by tumor environment which can
markedly suppress their antitumor activities.

Functions of macrophages are

regulated within a functional spectrum with M1 and M2 being the two extremes,
where the TAMs are more M2-polarized.

Pharmacological skewing of TAM

polarization from an M2–like phenotype to a full M1 phenotype has been shown to
sustain antitumor immunity (Sica et al., 2008).

As more evidences are becoming

available for the molecular mechanisms regulating the switch from M2 to M1,
targeting on TAMs polarization and reprogramming them to restore their antitumor
activities are a promising strategy for cancer treatment.
Although the mechanisms underlying macrophage polarization remain largely
unknown, the defective activation of NF-ĸB-mediated pathway seems to play an
important role.

IRF family members are critical mediators in the NF-ĸB signaling

network, regulating the productions of IFNs and ISGs.
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To test the idea of reactivating TAMs towards M1 phenotypes, we designed
this novel zymosan-adenovirus delivery system and did the pilot experiments.
We have shown firstly that the adenovirus-zymosan conjugates achieved
nearly

100%

transduction

efficiency.

It

is

documented

that

the

solid-phase-conjugated adenoviral vectors have certain functional advantages over
free viruses in the solution (Pandori et al., 2002).

In the present study, the

adenovirus-zymosan delivery system further supported the above notion in terms of
transduction efficiency.

Although we have not tested the side effects elicited by

zymosan and/or adenovirus, the present system could be an effective method to
transfer therapeutic genes into target cells, especially for localized delivery into
macrophages.
On the other hand, according to the preliminary data in our study, adenovirus
and zymosan undoubtedly serve as the first-level executors of macrophage activation.
It is known that zymosan can bind to TLR2 (Krishnan et al., 2007) which could
possibly lead to the activation of NF-κB and production of proinflammatory cytokines.
However, it is also reported that zymosan can not activate NF-κB in the rat liver
macrophages, but does activate activator protein-1 (AP-1) both in rat liver
macrophages and in the U937 human monocytic cell line (Tran-Thi et al., 1995)
(Pierce et al., 1996).
Although the mechanisms by which the cells recognize dsDNA viruses remain
largely unknown, it has been found that dsDNA viruses, such as adenovirus, can
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activate antigen-presenting cells (APC) via TLR-independent activation of IRF3
(Nociari et al., 2007). Furthermore, studies showed that adenovirus can initiate a
cascade of signaling transduction upon interaction with TLR9 (Barton, 2007).
One of the observations in our experiments is that RAW-Blue macrophage cell
line transfected by IRF genes mediated via adenovirus-zymosan conjugates had
increased production of NF-κB-AP-1-inducible SEAP, which indicates the activation
of NF-κB/AP-1 pathway in the transduced macrophages. Defective activation of
NF-κB is frequently observed in the TAMs isolated from established solid tumors
(Sica et al., 2000). Re-activate NF-κB or NF-κB-mediated signaling pathway could
be an effective way to induce production of a wide spectrum of proinflammatory
cytokines.

The current results from QUANTI-Blue assay were not definitive in

explaining whether the effect is elicited by IRF genes, since the expression of SEAP
was also up-regulated in the Zymosan-Ad-EGFP transduced macrophages.

Another

observation is, compared with the effect caused by IRF3 and Mut3 on SEAP
production, the super active IRF3 (Mut3) seems to be more effective in activating
macrophages.

More experiments with different conditions (especially different

MOIs and different time points) are needed to further validate this result.

As we

were unable to detect phosphorylated NF-κB-p65 in our samples using Western
blotting, the activation of NF-κB still needs to be analyzed by other methods or with
more protein loading. It is also possible that the NF-κB has been activated, but the
p65 subunit was not phosphorylated as the p65 phosphorylation has not been proved
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to be a required event for the transcriptional activity of NF-κB. Moreover, we were
trying to detect the phosphorylated p65 on Ser276, but the phosphorylation could be
on other sites.
Another observation in our study is that the NO productions did not increase
in those treated cells as expected, but on the contrary, the total NO level in the
untreated cells was higher than in the treated ones.

It is possible that the production

of NO in the infected macrophages is a rapid process, and the NO has been volatilized
after 48hr incubation. But for the untreated cells, the NO production measured
should reflect a stable status. It has been demonstrated in a lot of studies that NO
production is very unstable and the circumstances required for its release from
macrophages are controversial.

The NO production by macrophages can vary

greatly along with different cell types, incubation times and species (Albina, 1995).
Additionally, even if there is NO production, it does not necessarily indicate the
increased activities of macrophages in fighting against invaders (Vazquez-Torres et al.,
1995).
The secretion of a variety of proinflammatory cytokines is an important
characteristic for M1-polarized competent immune responses, including antitumor
effects.

The cytokines are critical indicators for evaluating the activity and polarity

of macrophages.

We have shown in this study that transfected macrophages

generally had increased production of M1-like cytokines. According to the studies
summarized in (Sica and Bronte, 2007), many of the up-regulated cytokines in our
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study are molecules downstream of NF-κB, including TNF-α, KC, CCL2-CCL5,
MIP-2 and CXCL10.

These cytokines could also be induced by IRF genes directly

or by IRF-induced interferons through autocrine and paracrine signaling.
Interestingly, the increased production of M2-like cytokine, such as IL-1ra, was also
observed in the transfected macrophages except the IRF3-transfected macrophages.
Granulocyte colony-stimulating factor (G-CSF) is different from GM-CSF or
M-CSF which has been reported to be potent M1- or M2-polarizing signal,
respectively (Fleetwood et al., 2007).

G-CSF is considered to be an important factor

in regulating neutrophil numbers and activities during inflammation (Lieschke et al.,
1994).

Soluble ICAM-1 (sICAM-1) is a member of Ig gene family and can mediate

cell-cell contact in different situations (Springer, 1990). Although there is no direct
evidence showing the role of sICAM-1 in enhancing M1-like phenotypes, it has been
suggested that sICAM-1 could enhance the recruitment of neutrophils and increase
expression levels of TNF-α and MIP-2 in lungs (Schmal et al., 1998). Both of
G-CSF and sICAM-1 are normally at very low level in circulation, but the levels can
increase markedly under stress conditions, such as infection (Hamilton, 2008),
(Schmal et al., 1998). In line with this notion, our study showed that there is no
detectable G-CSF and sICAM-1 in the untreated cells.

The up-regulation of

sICAM-1 and G-CSF in our treated cells could have a positive effect on macrophages
in the recruitment of ‘supporting forces’, i.e. other phagocytes, especially neutrophils.
As mentioned above, the zymosan particles and adenoviruses can interact with
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TLR receptors leading to proinflammatory responses, the production and/or
up-regulation of certain cytokines could come from three sources: the effect elicited
by the binding of zymosan to the TLR2; the effect from the cells sensing viral dsDNA
through TLR9-dependent and/or –independent pathways; and the effects directly from
the expression of the transfected IRF genes.
Moreover, there could be some other cytokines secreted in our samples, but
their levels were below the detection sensitivity of the cytokine array used in this
study. We plan to use methods with higher sensitivity to have a more detailed
analysis of the secreted cytokines in future studies.
These pilot experiments in the present study shed lights on this novel
adenovirus-zymosan conjugate-mediated delivery system as a potential way to
transfer therapeutic genes.

Further studies are needed to modify the parameters of

the system, including adenovirus/zymosan ratio, MOI, incubation time, etc.

It is also

necessary to do more experiment to confirm the results, for example, use nuclear
extract to do Western blotting because nuclear translocation is an important step in
NF-κB activation.

Additionally, future works also include in vitro and in vivo

transduce our candidate genes into mouse primary macrophages to further test their
possible antitumor activities.

Different combinations of the recombinant

adenoviruses containing the IRF genes will be co-transduced into the macrophages to
test the effects on macrophage activation.

Finally, it is of great importance to

evaluate the safety of the delivery system, especially the negative effects elicited by
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zymosan particles and adenoviruses.
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Appendix A Abbreviations
A
Ads: adenoviruses
ATF: activating transcription factor
C
CAR: coxsackie and adenovirus receptor
CARD: caspase recruitment domain
CBP: CREB binding protein
CCL: CC chemokine ligand
CL: cutaneous lymphoma
CML: chronic myelogenous leukemia
CREB: cAMP response element-binding protein
CSF: colony stimulating factor
CXCL: CXC chemokine ligand
D
DBD: DNA binding domain
E
ECM: extracellular matrix
EMAP: endothelial monocyte activating peptide
ERK: extracellular signal-regulated kinase
G
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GCSF: G-CSF, granulocyte colony-stimulating factor
GM-CSF: Granulocyte-macrophage colony-stimulating factor
H
HDV: helper-dependent adenoviral vector
HIF: hypoxia-inducible factor
HMG: high mobility group protein
HTH motif: helix-turn-helix motif
I
IAD: IRF association domain
ICAM: intercellular adhesion molecule
IFN: interferon
IFNAR: Interferon-Alpha Receptor
IFNGR: Interferon-Gamma Receptor
IFNLR: Interferon-Lambda Receptor
IL: interleukin
IL10R2: Interleukin 10 Receptor Chain 2
iNOS: inducible nitric oxide synthase
IRAK: IL-1-receptor-associated kinase
IRF: interferon regulatory factor
ISGs: interferon-stimulated genes
ISRE: IFN-stimulated response element
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J
JAK: Janus kinase
K
KC: CXCL1, CXC chemokine ligand 1
L
LPS: lipopolysaccharide
M
MAK: macrophage activated killer
MAPK: mitogen-activated protein kinase
MCP: macrophage chemoattractant protein
M-CSF: macrophage colony-stimulating factor
MDA-5: melanoma differentiation-associated gene-5
MDF: macrophage-derived chemotactic factor
MEF: mouse embryonic fibroblast
MHC: major histocompatibility complex
MIP-2: CXCL2, CXC chemokine ligand 2
MKP: MAPK phosphatase
MMP: matrix metalloproteinase
MMPI: synthetic MMP inhibitor
MyD88: myeloid differentiation primary response gene 88
N
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NK cells: natural killer cells
NLS: nuclear localization signals
NO: nitric oxide
P
PAI: plasminogen activator inhibitor
PBM: peripheral blood monocytes(s)
PGE2: prostaglandin E2
PM: peritoneal macrophage(s)
PML: promyelocytic leukemia
PRDI: positive regulatory domain I element
R
RIG-1: retinoid-inducible gene-1
S
sICAM-1: soluble intercellular adhesion molecule-1
SRR: serine-rich region
SSL motif: Ser-Ser-Leu motif
STAT protein: signal transducers and activators of transcription protein
T
TAM: tumor-associated macrophage
TDCF: tumor-derived chemotactic factor
TGF: transforming growth factor
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TIR: Toll/IL-1 receptor domain
TLR: toll-like receptor
TNF: tumor necrosis factor
TRAF-6: TNF receptor-associated factor 6
TRAM: TRIF-related adaptor molecule
TRIF: TIR-domain-containing adapter-inducing IFN-β
TSP 1: thrombospondin 1
V
VEGF: vascular endothelial growth factor
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Appendix B

Protocol for preparation of streptavidin-zymosan

Derivatization of ADH-Zymosan with SPDP:
1. Suspend 10mg ADH-Zymosan in 1ml PBS
2. Add 5μl SPDP solution (final conc. = 100μM)
3. Incubate with shaking for 2 hr, RT
4. Spin at 1000 × g for 5min, carefully suck off fluid and resuspend pellet in 1ml PBS
5. Repeat step 4 twice
6. Finally resuspend pellet in 1ml PBS
Derivatization of Streptavidin with SPDP:
1. Dissolve 1mg Streptavidin in 0.2ml PBS
2. Add 1.25μl SPDP solution, mix well (final conc. = 250μM, molar ratio
SPDP:streptavidin ~2.5)
3. Incubate for 2hr, RT
4. Remove residual reagent by spin chromatography on a 2ml Zeba Desalt Spin
Column (Pierce) equilibrated with PBS according to manufacturer’s instructions
Zymosan Streptavidin Conjugation:
1. To 1ml of SPDP-modified Zymosan (see above) add 10μl 1M DTT (final conc. =
10mM) (prepare freshly!)
2. Incubate with shaking for 30min, RT
3. Spin at 1000 × g for 5min, carefully suck off fluid and resuspend pellet in 1ml PBS
4. Repeat step 4 three times
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5. Finally resuspend pellet in 1ml PBS
6. Immediately add 50μl (~ 250μg) of SPDP-modified streptavidin (see above)
7. Incubate with shaking o.n., RT
8. Spin at 1000 × g for 5min; carefully suck off fluid and resuspend pellet in 1ml HBS
9. Repeat step 8 twice
10. Finally resuspend pellet in 1ml HBS
Remarks:
SPDP-modification of Zymosan will create ~108 protected sulfhydryl groups per
Zymosan particle, whereas SPDP-modification of streptavidin will create ~1 protected
sulfhydryl group per molecule.

Altogether, the given protocol will yield conjugates

with ~106 streptavidin molecules per Zymosan particle.
Buffers & Reagents:
1. ADH-Zymosan: prepared as described
2. SPDP-Solution: 20mM (6.25mg/ml) SPDP (Sigma) in water-free DMSO; store in
tightly sealed tube at – 20° C for no more than 4 weeks

Protocol: G. Schwamberger

last modified: 24-05-07

97

REFERENCES

Albina, J. E. (1995). On the expression of nitric oxide synthase by human
macrophages. Why no NO? J Leukoc Biol 58, 643-649.
Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A. (2001). Recognition of
double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature
413, 732-738.
Andreesen, R., Hennemann, B., and Krause, S. W. (1998). Adoptive immunotherapy
of cancer using monocyte-derived macrophages: rationale, current status, and
perspectives. J Leukoc Biol 64, 419-426.
Au, W. C., Moore, P. A., LaFleur, D. W., Tombal, B., and Pitha, P. M. (1998).
Characterization of the interferon regulatory factor-7 and its potential role in the
transcription activation of interferon A genes. J Biol Chem 273, 29210-29217.
Au, W. C., Yeow, W. S., and Pitha, P. M. (2001). Analysis of functional domains of
interferon regulatory factor 7 and its association with IRF-3. Virology 280, 273-282.
Azenshtein, E., Luboshits, G., Shina, S., Neumark, E., Shahbazian, D., Weil, M.,
Wigler, N., Keydar, I., and Ben-Baruch, A. (2002). The CC chemokine RANTES in
breast carcinoma progression: regulation of expression and potential mechanisms of
promalignant activity. Cancer Res 62, 1093-1102.
Baj-Krzyworzeka, M., Baran, J., Szatanek, R., Stankiewicz, D., Siedlar, M., and
Zembala, M. (2004). Prevention and reversal of tumor cell-induced monocyte
deactivation by cytokines, purified protein derivative (PPD), and anti-IL-10 antibody.
Cancer Immun 4, 8.
Barton, G. M. (2007). Viral recognition by Toll-like receptors. Semin Immunol 19,
33-40.
Biswas, S. K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., Bottazzi, B.,
Doni, A., Vincenzo, B., Pasqualini, F., et al. (2006). A distinct and unique
transcriptional program expressed by tumor-associated macrophages (defective
NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107, 2112-2122.
Biswas, S. K., Sica, A., and Lewis, C. E. (2008). Plasticity of macrophage function
during tumor progression: regulation by distinct molecular mechanisms. J Immunol
180, 2011-2017.

98

Borden, E. C. (2005). Review: Milstein Award lecture: interferons and cancer: where
from here? J Interferon Cytokine Res 25, 511-527.
Bouma-ter Steege, J. C., Baeten, C. I., Thijssen, V. L., Satijn, S. A., Verhoeven, I. C.,
Hillen, H. F., Wagstaff, J., and Griffioen, A. W. (2004). Angiogenic profile of breast
carcinoma determines leukocyte infiltration. Clin Cancer Res 10, 7171-7178.
Chow, W. A., Fang, J. J., and Yee, J. K. (2000). The IFN regulatory factor family
participates in regulation of Fas ligand gene expression in T cells. J Immunol 164,
3512-3518.
Eisenbeis, C. F., Singh, H., and Storb, U. (1995). Pip, a novel IRF family member, is a
lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 9,
1377-1387.
Elgert, K. D., Alleva, D. G., and Mullins, D. W. (1998). Tumor-induced immune
dysfunction: the macrophage connection. J Leukoc Biol 64, 275-290.
Elnemr, A., Ohta, T., Yachie, A., Fushida, S., Ninomiya, I., Nishimura, G. I.,
Yamamoto, M., Ohkuma, S., and Miwa, K. (2000). N-ethylmaleimide-enhanced
phosphatidylserine externalization of human pancreatic cancer cells and immediate
phosphatidylserine-mediated phagocytosis by macrophages. Int J Oncol 16,
1111-1116.
Escalante, C. R., Yie, J., Thanos, D., and Aggarwal, A. K. (1998). Structure of IRF-1
with bound DNA reveals determinants of interferon regulation. Nature 391, 103-106.
Fidler, I. J. (1974). Inhibition of pulmonary metastasis by intravenous injection of
specifically activated macrophages. Cancer Res 34, 1074-1078.
Fleetwood, A. J., Lawrence, T., Hamilton, J. A., and Cook, A. D. (2007).
Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage
CSF-dependent macrophage phenotypes display differences in cytokine profiles and
transcription factor activities: implications for CSF blockade in inflammation. J
Immunol 178, 5245-5252.
Gresser, I., and Belardelli, F. (2002). Endogenous type I interferons as a defense
against tumors. Cytokine Growth Factor Rev 13, 111-118.
Gresser, I., Bourali, C., Levy, J. P., Fontaine-Brouty-Boye, D., and Thomas, M. T.
(1969). Increased survival in mice inoculated with tumor cells and treated with
interferon preparations. Proc Natl Acad Sci USA 63, 51-57.

99

Grimshaw, M. J., and Balkwill, F. R. (2001). Inhibition of monocyte and macrophage
chemotaxis by hypoxia and inflammation--a potential mechanism. Eur J Immunol 31,
480-489.
Hagemann T., S. C. R., M. Schulz, L. Trumper,F. R. Balkwill & C. Binder (2004).
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with
macrophages is due to TNF-alpha dependent up-regulation of matrix
metalloproteinases. Carcinogenesis 25, 1542-1549.
Hamilton, J. A. (2008). Colony-stimulating factors in inflammation and autoimmunity.
Nat Rev Immunol 8, 533-544.
Harada, H., Kitagawa, M., Tanaka, N., Yamamoto, H., Harada, K., Ishihara, M., and
Taniguchi, T. (1993). Anti-oncogenic and oncogenic potentials of interferon
regulatory factors-1 and -2. Science 259, 971-974.
Harada, H., Takahashi, E., Itoh, S., Harada, K., Hori, T. A., and Taniguchi, T. (1994).
Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and
IRF-2 genes: implications for a gene network in the interferon system. Mol Cell Biol
14, 1500-1509.
Heuser, M., van der Kuip, H., Falini, B., Peschel, C., Huber, C., and Fischer, T. (1998).
Induction of the pro-myelocytic leukaemia gene by type I and type II interferons.
Mediators Inflamm 7, 319-325.
Honda, K., and Taniguchi, T. (2006). IRFs: master regulators of signalling by Toll-like
receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6, 644-658.
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N.,
Ohba, Y., Takaoka, A., Yoshida, N., and Taniguchi, T. (2005). IRF-7 is the master
regulator of type-I interferon-dependent immune responses. Nature 434, 772-777.
Hoshino, Y., Hatake, K., Kasahara, T., Takahashi, Y., Ikeda, M., Tomizuka, H.,
Ohtsuki, T., Uwai, M., Mukaida, N., Matsushima, K., and et al. (1995). Monocyte
chemoattractant protein-1 stimulates tumor necrosis and recruitment of macrophages
into tumors in tumor-bearing nude mice: increased granulocyte and macrophage
progenitors in murine bone marrow. Exp Hematol 23, 1035-1039.
Huang, S., Van Arsdall, M., Tedjarati, S., McCarty, M., Wu, W., Langley, R., and
Fidler, I. J. (2002). Contributions of stromal metalloproteinase-9 to angiogenesis and
growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94, 1134-1142.

100

Ibe, S., Qin, Z., Schuler, T., Preiss, S., and Blankenstein, T. (2001). Tumor rejection
by disturbing tumor stroma cell interactions. J Exp Med 194, 1549-1559.
Kano, A., Haruyama, T., Akaike, T., and Watanabe, Y. (1999). IRF-1 is an essential
mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured
hepatocytes. Biochem Biophys Res Commun 257, 672-677.
Karin, M., and Greten, F. R. (2005). NF-kappaB: linking inflammation and immunity
to cancer development and progression. Nat Rev Immunol 5, 749-759.
Karin, M., Lawrence, T., and Nizet, V. (2006). Innate immunity gone awry: linking
microbial infections to chronic inflammation and cancer. Cell 124, 823-835.
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu,
S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006). Differential roles of MDA5 and
RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105.
Kawai, T., Sato, S., Ishii, K. J., Coban, C., Hemmi, H., Yamamoto, M., Terai, K.,
Matsuda, M., Inoue, J., Uematsu, S., et al. (2004). Interferon-alpha induction through
Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat
Immunol 5, 1061-1068.
Kim, T. K., Kim, T. H., and Maniatis, T. (1998). Efficient recruitment of TFIIB and
CBP-RNA polymerase II holoenzyme by an interferon-beta enhanceosome in vitro.
Proc Natl Acad Sci U S A 95, 12191-12196.
Kim, T. K., and Maniatis, T. (1997). The mechanism of transcriptional synergy of an
in vitro assembled interferon-beta enhanceosome. Mol Cell 1, 119-129.
Knowles, H. J., and Harris, A. L. (2007). Macrophages and the hypoxic tumour
microenvironment. Front Biosci 12, 4298-4314.
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K.,
Langer, J. A., Sheikh, F., Dickensheets, H., and Donnelly, R. P. (2003). IFN-lambdas
mediate antiviral protection through a distinct class II cytokine receptor complex. Nat
Immunol 4, 69-77.
Krishnan, J., Selvarajoo, K., Tsuchiya, M., Lee, G., and Choi, S. (2007). Toll-like
receptor signal transduction. Exp Mol Med 39, 421-438.
Kroger, A., Koster, M., Schroeder, K., Hauser, H., and Mueller, P. P. (2002). Activities
of IRF-1. J Interferon Cytokine Res 22, 5-14.

101

Leek, R. D., Hunt, N. C., Landers, R. J., Lewis, C. E., Royds, J. A., and Harris, A. L.
(2000). Macrophage infiltration is associated with VEGF and EGFR expression in
breast cancer. J Pathol 190, 430-436.
Lei, H., Ju, D. W., Yu, Y., Tao, Q., Chen, G., Gu, S., Hamada, H., and Cao, X. (2000).
Induction of potent antitumor response by vaccination with tumor lysate-pulsed
macrophages engineered to secrete macrophage colony-stimulating factor and
interferon-gamma. Gene Ther 7, 707-713.
Lenardo, M. J., Fan, C. M., Maniatis, T., and Baltimore, D. (1989). The involvement
of NF-kappa B in beta-interferon gene regulation reveals its role as widely inducible
mediator of signal transduction. Cell 57, 287-294.
Lieschke, G. J., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K.
J., Basu, S., Zhan, Y. F., and Dunn, A. R. (1994). Mice lacking granulocyte
colony-stimulating factor have chronic neutropenia, granulocyte and macrophage
progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84,
1737-1746.
Lin, E. Y., Nguyen, A. V., Russell, R. G., and Pollard, J. W. (2001).
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.
J Exp Med 193, 727-740.
Lin, R., Heylbroeck, C., Pitha, P. M., and Hiscott, J. (1998). Virus-dependent
phosphorylation of the IRF-3 transcription factor regulates nuclear translocation,
transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 18,
2986-2996.
Lin, R., Mamane, Y., and Hiscott, J. (1999). Structural and functional analysis of
interferon regulatory factor 3: localization of the transactivation and autoinhibitory
domains. Mol Cell Biol 19, 2465-2474.
Mario Koster, S. K., Fred Schaper and Hansjorg Hauser (1995). Proliferation control
of mammalian cells by the tumor suppressor IRF-1. Cytotechnology 18, 67-75.
Matsumoto, M., Tanaka, N., Harada, H., Kimura, T., Yokochi, T., Kitagawa, M.,
Schindler, C., and Taniguchi, T. (1999). Activation of the transcription factor ISGF3
by interferon-gamma. Biol Chem 380, 699-703.

102

Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I.
J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. (1997). Hypoxia-inducible factor-1
modulates gene expression in solid tumors and influences both angiogenesis and
tumor growth. Proc Natl Acad Sci U S A 94, 8104-8109.
Miyamoto, M., Fujita, T., Kimura, Y., Maruyama, M., Harada, H., Sudo, Y., Miyata, T.,
and Taniguchi, T. (1988). Regulated expression of a gene encoding a nuclear factor,
IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54, 903-913.
Mostafa, L. K., Jones, D. B., and Wright, D. H. (1980). Mechanism of the induction
of angiogenesis by human neoplastic lymphoid tissue: studies on the chorioallantoic
membrane (CAM) of the chick embryo. J Pathol 132, 191-205.
Nesbit, M., Schaider, H., Miller, T. H., and Herlyn, M. (2001). Low-level monocyte
chemoattractant protein-1 stimulation of monocytes leads to tumor formation in
nontumorigenic melanoma cells. J Immunol 166, 6483-6490.
Nociari, M., Ocheretina, O., Schoggins, J. W., and Falck-Pedersen, E. (2007). Sensing
infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals
activation of the interferon regulatory factor 3 master regulator. J Virol 81, 4145-4157.
O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane,
W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994). Angiostatin: a novel angiogenesis
inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell
79, 315-328.
Ohmori, Y., and Hamilton, T. A. (1997). IL-4-induced STAT6 suppresses
IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. J
Immunol 159, 5474-5482.
Okumura, A., Alce, T., Lubyova, B., Ezelle, H., Strebel, K., and Pitha, P. M. (2008).
HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3
for degradation. Virology 373, 85-97.
Pagano, L. Z. a. J. S. (1997). IRF-7, a new interferon regulatory factor associated with
Epstein-Barr virus latency. Mol Cell Biol 17, 5748?5757.
Pandori, M., Hobson, D., and Sano, T. (2002). Adenovirus-microbead conjugates
possess enhanced infectivity: a new strategy for localized gene delivery. Virology 299,
204-212.

103

Pestka, S., Langer, J. A., Zoon, K. C., and Samuel, C. E. (1987). Interferons and their
actions. Annu Rev Biochem 56, 727-777.
Petrella, B. L., Lohi, J., and Brinckerhoff, C. E. (2005). Identification of membrane
type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von
Hippel-Lindau renal cell carcinoma. Oncogene 24, 1043-1052.
Pierce, R. A., Sandefur, S., Doyle, G. A., and Welgus, H. G. (1996). Monocytic cell
type-specific transcriptional induction of collagenase. J Clin Invest 97, 1890-1899.
Platanias, L. C. (2005). Mechanisms of type-I- and type-II-interferon-mediated
signalling. Nat Rev Immunol 5, 375-386.
Politis, A. D., Sivo, J., Driggers, P. H., Ozato, K., and Vogel, S. N. (1992). Modulation
of interferon consensus sequence binding protein mRNA in murine peritoneal
macrophages. Induction by IFN-gamma and down-regulation by IFN-alpha,
dexamethasone, and protein kinase inhibitors. J Immunol 148, 801-807.
Rego, E. M., Wang, Z. G., Peruzzi, D., He, L. Z., Cordon-Cardo, C., and Pandolfi, P. P.
(2001). Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp
Med 193, 521-529.
Reiss, Y., Hoch, G., Deutsch, U., and Engelhardt, B. (1998). T cell interaction with
ICAM-1-deficient endothelium in vitro: essential role for ICAM-1 and ICAM-2 in
transendothelial migration of T cells. Eur J Immunol 28, 3086-3099.
Richardson, R. J., Dixon, J., Malhotra, S., Hardman, M. J., Knowles, L.,
Boot-Handford, R. P., Shore, P., Whitmarsh, A., and Dixon, M. J. (2006). Irf6 is a key
determinant of the keratinocyte proliferation-differentiation switch. Nat Genet 38,
1329-1334.
Ritchie, D., Mileshkin, L., Wall, D., Bartholeyns, J., Thompson, M., Coverdale, J.,
Lau, E., Wong, J., Eu, P., Hicks, R. J., and Prince, H. M. (2007). In vivo tracking of
macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer
Immunol Immunother 56, 155-163.
Romano, G. (2007). The standpoint of gene therapy programs. Drug News Perspect 20,
335-343.

104

Romieu-Mourez, R., Solis, M., Nardin, A., Goubau, D., Baron-Bodo, V., Lin, R.,
Massie, B., Salcedo, M., and Hiscott, J. (2006). Distinct roles for IFN regulatory
factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human
macrophages. Cancer Res 66, 10576-10585.
Saccani, A., Schioppa, T., Porta, C., Biswas, S. K., Nebuloni, M., Vago, L., Bottazzi,
B., Colombo, M. P., Mantovani, A., and Sica, A. (2006). p50 nuclear factor-kappaB
overexpression in tumor-associated macrophages inhibits M1 inflammatory responses
and antitumor resistance. Cancer Res 66, 11432-11440.
Salkowski, C. A., Kopydlowski, K., Blanco, J., Cody, M. J., McNally, R., and Vogel,
S. N. (1999). IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout
mice. J Immunol 163, 1529-1536.
Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S. K., Doni, A., Rapisarda, A.,
Bernasconi, S., Saccani, S., Nebuloni, M., Vago, L., et al. (2003). Regulation of the
chemokine receptor CXCR4 by hypoxia. J Exp Med 198, 1391-1402.
Schmal, H., Czermak, B. J., Lentsch, A. B., Bless, N. M., Beck-Schimmer, B., Friedl,
H. P., and Ward, P. A. (1998). Soluble ICAM-1 activates lung macrophages and
enhances lung injury. J Immunol 161, 3685-3693.
Schroder, K., Hertzog, P. J., Ravasi, T., and Hume, D. A. (2004). Interferon-gamma:
an overview of signals, mechanisms and functions. J Leukoc Biol 75, 163-189.
Seiler, M. P., Cerullo, V., and Lee, B. (2007). Immune response to helper dependent
adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther 7,
297-305.
Sen, G. C., and Lengyel, P. (1992). The interferon system. A bird's eye view of its
biochemistry. J Biol Chem 267, 5017-5020.
Sharf, R., Meraro, D., Azriel, A., Thornton, A. M., Ozato, K., Petricoin, E. F., Larner,
A. C., Schaper, F., Hauser, H., and Levi, B. Z. (1997). Phosphorylation events
modulate the ability of interferon consensus sequence binding protein to interact with
interferon regulatory factors and to bind DNA. J Biol Chem 272, 9785-9792.
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T.
E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003). IL-28, IL-29 and
their class II cytokine receptor IL-28R. Nat Immunol 4, 63-68.

105

Shimura, S., Yang, G., Ebara, S., Wheeler, T. M., Frolov, A., and Thompson, T. C.
(2000). Reduced infiltration of tumor-associated macrophages in human prostate
cancer: association with cancer progression. Cancer Res 60, 5857-5861.
Sica, A., and Bronte, V. (2007). Altered macrophage differentiation and immune
dysfunction in tumor development. J Clin Invest 117, 1155-1166.
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M.,
Biswas, S. K., Allavena, P., and Mantovani, A. (2008). Macrophage polarization in
tumour progression. Semin Cancer Biol.
Sica, A., Rubino, L., Mancino, A., Larghi, P., Porta, C., Rimoldi, M., Solinas, G.,
Locati, M., Allavena, P., and Mantovani, A. (2007). Targeting tumour-associated
macrophages. Expert Opin Ther Targets 11, 1219-1229.
Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., van Damme, J., and
Mantovani, A. (2000). Autocrine production of IL-10 mediates defective IL-12
production and NF-kappa B activation in tumor-associated macrophages. J Immunol
164, 762-767.
Solis, M., Goubau, D., Romieu-Mourez, R., Genin, P., Civas, A., and Hiscott, J.
(2006). Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and
control of anti-tumor activity in primary macrophages. Biochem Pharmacol 72,
1469-1476.
Springer, T. A. (1990). Adhesion receptors of the immune system. Nature 346,
425-434.
Steele, R. J., Eremin, O., Brown, M., and Hawkins, R. A. (1984). A high macrophage
content in human breast cancer is not associated with favourable prognostic factors.
Br J Surg 71, 456-458.
Stockinger, S., Reutterer, B., Schaljo, B., Schellack, C., Brunner, S., Materna, T.,
Yamamoto, M., Akira, S., Taniguchi, T., Murray, P. J., et al. (2004). IFN regulatory
factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a
TLR- and Nod2-independent mechanism. J Immunol 173, 7416-7425.
Sunderkotter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., and Sorg, C. (1994).
Macrophages and angiogenesis. J Leukoc Biol 55, 410-422.

106

Taieb, J., Chaput, N., Menard, C., Apetoh, L., Ullrich, E., Bonmort, M., Pequignot, M.,
Casares, N., Terme, M., Flament, C., et al. (2006). A novel dendritic cell subset
involved in tumor immunosurveillance. Nat Med 12, 214-219.
Takahasi, K., Suzuki, N. N., Horiuchi, M., Mori, M., Suhara, W., Okabe, Y., Fukuhara,
Y., Terasawa, H., Akira, S., Fujita, T., and Inagaki, F. (2003). X-ray crystal structure of
IRF-3 and its functional implications. Nat Struct Biol 10, 922-927.
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S.,
Imai, K., Shibue, T., Honda, K., and Taniguchi, T. (2003). Integration of
interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral
defence. Nature 424, 516-523.
Tanaka, N., Ishihara, M., Lamphier, M. S., Nozawa, H., Matsuyama, T., Mak, T. W.,
Aizawa, S., Tokino, T., Oren, M., and Taniguchi, T. (1996). Cooperation of the tumour
suppressors IRF-1 and p53 in response to DNA damage. Nature 382, 816-818.
Taniguchi, T., Fujii-Kuriyama, Y., and Muramatsu, M. (1980). Molecular cloning of
human interferon cDNA. Proc Natl Acad Sci U S A 77, 4003-4006.
Taniguchi, T., Ogasawara, K., Takaoka, A., and Tanaka, N. (2001). IRF family of
transcription factors as regulators of host defense. Annu Rev Immunol 19, 623-655.
Tran-Thi, T. A., Decker, K., and Baeuerle, P. A. (1995). Differential activation of
transcription factors NF-kappa B and AP-1 in rat liver macrophages. Hepatology 22,
613-619.
Urosevic, M., Fujii, K., Calmels, B., Laine, E., Kobert, N., Acres, B., and Dummer, R.
(2007). Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene
transfer contributes to the regression of cutaneous lymphomas. J Clin Invest 117,
2834-2846.
Utsugi, T., Schroit, A. J., Connor, J., Bucana, C. D., and Fidler, I. J. (1991). Elevated
expression of phosphatidylserine in the outer membrane leaflet of human tumor cells
and recognition by activated human blood monocytes. Cancer Res 51, 3062-3066.
Vazquez-Torres, A., Jones-Carson, J., and Balish, E. (1995). Nitric oxide production
does not directly increase macrophage candidacidal activity. Infect Immun 63,
1142-1144.
Vousden, K. H., and Lu, X. (2002). Live or let die: the cell's response to p53. Nat Rev
Cancer 2, 594-604.

107

Wilbanks, G. D., Ahn, M. C., Beck, D. A., and Braun, D. P. (1999). Tumor
cytotoxicity of peritoneal macrophages and peripheral blood monocytes from patients
with ovarian, endometrial, and cervical cancer. Int J Gynecol Cancer 9, 427-432.
Xiang, Y., Wang, Z., Murakami, J., Plummer, S., Klein, E. A., Carpten, J. D., Trent, J.
M., Isaacs, W. B., Casey, G., and Silverman, R. H. (2003). Effects of RNase L
mutations associated with prostate cancer on apoptosis induced by
2',5'-oligoadenylates. Cancer Res 63, 6795-6801.
Zhang, X., Kon, T., Wang, H., Li, F., Huang, Q., Rabbani, Z. N., Kirkpatrick, J. P.,
Vujaskovic, Z., Dewhirst, M. W., and Li, C. Y. (2004). Enhancement of
hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of
small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 64,
8139-8142.

108

